

BAR-Seq Clonal Tracking of Gene Edited Cells

Samuele Ferrari^{1,2,*,#}, Stefano Beretta^{1,*}, Aurelien Jacob^{1,3}, Davide Cittaro⁴, Luisa Albano¹, Ivan Merelli^{1,5,†}, Luigi Naldini^{1,2,†}, Pietro Genovese^{1,†}.

¹San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan (MI), Italy.

²Vita-Salute San Raffaele University, 20132 Milan (MI), Italy.

³Milano-Bicocca University, 20900 Monza (MB), Italy.

⁴Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, 20132 Milan (MI), Italy.

⁵National Research Council, Institute for Biomedical Technologies, 20090 Segrate (MI), Italy.

*Equally contributing Authors.

†These Authors share senior authorship.

PG current address is: Gene Therapy Program, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Department of Pediatric Oncology, Harvard Medical School, Boston, MA, USA.

Corresponding author: ferrari.samuele@hsr.it

RELATED LINKS

Key references using this protocol

Ferrari S, Jacob A, Beretta S, Unali G, Albano L, Vavassori V, Cittaro D, Lazarevic D, Brombin C, Cugnata F, Kajaste-Rudnitski A, Merelli I, Genovese P, Naldini L. *Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking*. Nat Biotechnol. 2020 Nov;38(11):1298-1308. doi: 10.1038/s41587-020-0551-y. Epub 2020 Jun 29.

ABSTRACT

*Gene editing by engineered nucleases has revolutionized the field of gene therapy by enabling targeted and precise modification of the genome. However, the limited availability of methods for clonal tracking of edited cells resulted in paucity of information on diversity, abundance and behavior of the engineered clones. Here, we detail the wet and bioinformatic BAR-Seq pipeline, a barcoding-based strategy for clonal tracking of cells harboring homology-directed targeted integration. We present the BAR-Seq web application, an online freely available and easy-to-use software which allows to perform clonal tracking analyses on raw sequencing data **without any computational***

35 *resources or advanced bioinformatic skills. BAR-Seq can be applied to most editing strategies and*
36 *we describe its use to investigate clonal dynamics of human edited hematopoietic stem/progenitor*
37 *cells in xenotransplanted hosts. Notably, BAR-Seq may be applied both in basic and translational*
38 *research contexts to investigate the biology of edited cells and stringently compare editing protocols*
39 *at clonal level. Our BAR-Seq pipeline allows library preparation and validation in few days and*
40 *clonal analyses of edited cell populations in one week.*

41

42 INTRODUCTION

43 Viral vectors are widely exploited to transfer genetic information into cells of interest. Gene
44 therapy takes advantage of viral vectors to introduce therapeutic transgenes in patients' cells and,
45 therefore, holds great promise for the treatment of several diseases¹. The semi-random genomic
46 integration of some viral vectors, such as gamma-retroviral and lentiviral vectors (LV), enables
47 univocal and permanent marking of genetically modified cells and their progeny, thus identifying cell
48 clones which can be tracked over time and through space by means of vector integration sites². Clonal
49 tracking of genetically modified cells in preclinical and clinical studies expanded the knowledge on
50 safety and effectiveness of gene therapy, as well as giving remarkable insights on target cell biology
51 and differentiation³⁻⁷.

52 In the last years, gene editing has broadened the scope and means of genetic manipulation by
53 allowing precise integration in pre-selected safe genomic loci or *in situ* functional correction of a
54 mutant gene⁸. Engineered nucleases, such as CRISPR/Cas, are used to induce a DNA double strand
55 break (DSB) at the locus of interest, which can then be repaired by either the non-homologous end
56 joining (NHEJ) or the homology-directed repair (HDR) cellular machinery (**Fig. 1a**). The NHEJ
57 pathway rejoins the free DNA ends of the break while often introducing small base insertion or
58 deletions (indels), thus leaving a permanent genetic scar at the edited locus. Conversely, high-fidelity
59 HDR pathway can repair the DSB using a DNA template bearing homology to the target site.

60 Clonal tracking of edited cells can provide relevant information on the complexity and
61 dynamics of edited cell clones, thus expanding the characterization of the engineered cell product and
62 guiding its development and optimization in view of perspective clinical translation. Genomic scars
63 introduced by NHEJ might provide a surrogate clonal tracker in applications aiming at gene
64 disruption, albeit underpowered by the recurring generation of few dominant indels. On the other
65 hand, gene correction or targeted integration strategies based on HDR lack such possibility, as all
66 editing events will have the same sequence. Recently, we developed a barcoding-based strategy
67 (BAR-Seq) that allows clonal tracking of edited cells by means of unique molecular identifiers
68 (barcodes, BARs) embedded in the DNA template for HDR⁹. Molecular barcoding is a well-

69 established and successful method for lineage and cell tracking^{7,10,11}. BAR-Seq is a versatile and
70 portable “three-steps” clonal tracking pipeline (**Fig. 1b**) based on:

- 71 i) generation of barcoded HDR template libraries;
- 72 ii) editing of the locus of interest in the selected target cell population (here hematopoietic
73 stem/progenitor cells, HSPCs) using the editing nuclease of choice and the barcoded
74 template library;
- 75 iii) deep sequencing of BAR-Seq amplicons from the edited cells or their progeny at
76 different times post-treatment and bioinformatic analyses for the retrieval of BAR
77 sequences and their abundances.

78 Here we describe the BAR-Seq workflow applied to human HSPC gene editing and report a
79 robust experimental and bioinformatic pipeline to assess clonal composition of edited cells. BAR-
80 Seq enables: i) characterization of the *in vivo* repopulation capacity of gene edited human HSPCs
81 transplanted in murine recipients; ii) validation of improved editing protocols; and iii) identification
82 of experimental conditions preserving broader clonal repertoire of edited cells in recipient
83 hematopoiesis.

84 Additionally, we provide a flexible, freely available and user-friendly web application
85 (<http://www.bioinfotiget.it/barseq>), which eases and speeds up clonal tracking analyses of gene edited
86 cells from raw fastq sequencing data. **Of note, this web application and its bioinformatic pipeline are**
87 **suitable for clonal tracking analyses based on viral barcoded vectors, thus providing a useful tool for**
88 **viral or gene editing clonal tracking also by researchers with limited programming experience.**

89

90 APPLICATIONS OF THE METHOD

91 BAR-Seq can conceivably be applied to any cell type of interest from any eukaryotic species.
92 Templated sequence editing will be more efficient in actively cycling cells, since HDR is restricted
93 to S/G2 phase of the cell cycle¹². Quiescent and slowly cycling cells, such as HSPCs, are less
94 permissive to HDR¹³. We did not observe any detrimental consequence of introducing BAR in the
95 HDR template, neither on HDR efficiency nor on cellular response to the editing procedure⁹.

96 BAR-Seq can be applied to bulk *ex vivo* cultured cells and used to track engraftment and
97 lineage output upon transplantation. The high sensitivity of the barcoding-based platform allows to
98 assess clonal abundance and distribution even within rare sorted cell subpopulations, such as
99 hematopoietic progenitors.

100 BAR-Seq is expected to be compatible with any engineered nuclease, including Zinc Finger
101 Nucleases (ZFN), Transcriptional activator-like effector nucleases (TALEN) and CRISPR/Cas

102 variants. In our studies, we successfully used ZFN (unpublished data) and CRISPR/Cas9⁹ as
103 nucleases.

104 Barcodes can be embedded in HDR templates designed to target virtually any genomic locus,
105 both in somatic⁹ and sex-linked chromosomes (unpublished data), albeit some considerations should
106 be made in the former case (see “Limitations”). BAR-Seq could be adapted to different delivery
107 vehicles of HDR templates. Therefore plasmid, double stranded (ds)DNA, single stranded (ss)DNA,
108 integrase-defective lentiviral vector (IDLV) and adeno-associated vector (AAV) can be used for
109 BAR-Seq experiments. In our studies, we successfully used AAV serotype 6 (AAV6)⁹, which has
110 been shown to efficiently transduce hematopoietic cells¹⁴, and VSV.G pseudotyped IDLV
111 (unpublished data). Barcodes can conceivably be included in any part of the HDR template, either in
112 transcribed or non-transcribed regions. The use of transcribed barcodes (eBAR-Seq) would allow
113 powerful combination of single-cell transcriptomic studies with lineage tracking information, as
114 previously reported in other studies based on barcoded LV¹⁵.

115 Finally, BAR-Seq bioinformatic pipeline also identifies the most abundant (“dominant”) cell
116 clones in the HDR-edited population, thus focusing sharing analyses on those clones more robustly
117 contributing to the *in vitro* outgrowth or to host repopulation. In our experimental settings, this
118 approach allowed to study the clonal behavior of long-term repopulating HSPC clones and removed
119 the background signal derived from short-lived cells providing limited output. Of note, the frequency
120 of dominant HSPC clones long-term after transplant in murine recipients, as calculated by BAR-Seq,
121 well fitted with estimates in limiting-dilution repopulation assays^{16,17}, thus validating our clonal
122 tracking pipeline. Of note, clonal analysis of the most abundant clones may find its application
123 beyond hematopoiesis, including most setting based on host repopulation and modelling of clonal
124 expansion.

125

126 COMPARISON WITH OTHER METHODS

127 In the gene editing field, fluorescent reporter genes (e.g. GFP) have been extensively used to
128 provide a surrogate and easy readout to track and quantify *bona-fide* HDR-edited cells and their
129 progeny^{14,18,19}. However, this approach does not allow to discriminate among different edited clones.
130 BAR-Seq enables clonal tracking of HDR-edited cells at single-cell resolution, even in absence of
131 reporter-expressing cassettes, by offering the possibility to investigate proliferation, differentiation,
132 self-renewal and long-term maintenance of HDR-edited cell clones, as well as to stringently compare
133 different editing protocols and reagents.

134 Genomic scars (i.e. indels) introduced by NHEJ at the nuclease target site can be exploited as
135 markers of clonality and for lineage tracking^{20,21} by measuring indel diversity. Of note, the clonal

136 diversity might be underestimated by biased insertion/deletion of nucleotides²² or restoration of the
137 wildtype (WT) sequence. Furthermore, NHEJ or microhomology-mediated “large” deletions might
138 result in dropout of cell clones due to the loss of primer binding sites on the target region²³. Finally,
139 this approach cannot interrogate HDR-edited cells.

140

141 **EXPERIMENTAL DESIGN**

142 **Design and production of the barcoded plasmid library.** The conventional (non-barcoded)
143 template for HDR is composed of a transgene or therapeutic cassette framed by two sequences bearing
144 homologies for the intended target site (**Fig. 2a, left**). The maximal length of the HDR template is
145 dependent on the cargo capacity of the vector used for its delivery, which is approximately 4.7 and 9
146 kilobases (kb) for AAV and IDLV, respectively. Protocols describing the optimal configuration of
147 conventional HDR template have been previously published²⁴⁻²⁶. **The non-barcoded template for
148 HDR can be designed and purchased by gene synthesis services and then subcloned into the
149 appropriate backbone (e.g. any transfectable plasmid, pAAV-MCS or pCCL-LV transfer plasmids)
150 depending on the vehicle chosen for template delivery.** Here, we highlight the key points for the
151 generation of plasmid libraries carrying the BAR-Seq HDR template.

152 First, we advise to generate the conventional HDR template in a backbone suitable for the
153 final purpose. For AAV, the whole HDR template must be cloned between inverted terminal repeats
154 (ITRs), **conventionally** derived from AAV2. Alternatively, the HDR template can be cloned in a third-
155 generation self-inactivating transfer construct suitable for IDLV production or in any transfectable
156 plasmid DNA. In any case, two unique restriction sites generating incompatible ends (such as SphI
157 and Bsu36I) spaced by >10 nucleotides (nts) should be included at the intended site for BAR cloning
158 to avoid BAR concatemers and facilitate the generation of the BAR-Seq HDR template library. BAR
159 must be cloned either inside (transcribed eBAR) or outside (genomic BAR) an expressed cassette and
160 always between homology arms to ensure its incorporation into the genome upon HDR (**Fig. 2a,
161 right**). BAR length and consensus sequence must be carefully evaluated in order to reach an adequate
162 library complexity (i.e. number of unique molecular identifier) and minimize biases in BAR structure.
163 BAR-Seq requires forward and reverse primers binding upstream and downstream BAR cloning site.
164 To exclusively amplify the on-target BARs, one of the two primers must bind the genomic region
165 outside the homology arm (“In-Out” PCR approach) (**Fig. 2b**).

166 The maximal theoretical complexity of the library having length x can be calculated as 4^x ,
167 assuming all positions can include all nucleotides. More in general, the complexity is calculated as C
168 $= \prod D_i$, where D_i is the number of allowed nucleotides in position i , and the effective BAR length is
169 $\log_4(C)$. The decision about BAR length strictly depends on the expected clonality of the cell

170 population of interest. Indeed, the longer is the BAR, the more complex will be the library and the
171 lower will be the probability of tagging >1 HDR-edited cell with the same BAR^{2,27}. To minimize the
172 chance of having two individual cell clones tagged with the same BAR, we recommend an effective
173 BAR length >12 nucleotides and the library complexity >10³-fold higher than the expected
174 complexity of the HDR-edited cell population. **Indeed, the risk of having two cells sharing the same
175 barcode (collision) follows a binomial distribution. However, this distribution can be approximated
176 by a Poisson distribution with $\lambda = n/b$, where λ is the inverse of the aforementioned threshold (10⁻³),
177 when the number of cells (n) and barcodes (b) is sufficiently high, as in this protocol and other
178 barcoding techniques. Therefore, the probability of uniquely barcoded cells is $P_{\text{Poisson}}(0; \lambda)$, which is
179 >99% already when $\lambda = 10^{-2}$, corresponding to a 1:100 proportion (where P_{Poisson} is the probability
180 mass function of the Poisson distribution) (**Supplementary Table 1**). Previous works indicate that
181 even 1:100 proportion²⁸ or 1:50 proportion¹¹ are sufficient to minimize collision events. Since the
182 ratio is calculated on the theoretical complexity, we choose a conservative rule of thumb to take into
183 account the subsequent reduction of complexity due to the efficiency of the library preparation step.**
184 In the BAR structure, some positions may be fixed or limited to few bases to avoid generation of
185 BARs carrying the cloning restriction sites, which would be preferentially ligated, and thus
186 overrepresented, in the library because of shorter length²⁷. For this purpose, we designed the BAR
187 consensus sequence as 5'-NNYNNNTNTNNNNRRTNDNNHH-3', having a maximal theoretical
188 complexity of $\sim 2.899 \times 10^{10}$ (instead of $\sim 1.759 \times 10^{23}$ with Ns only). Of note, the real complexity of
189 the library will be lower than the theoretical one due to bottlenecks in cloning and plasmid/viral
190 preparation. With our protocol, we easily obtained final library complexity from 3×10^5 to 8×10^5
191 unique BARs with homogeneous representation. **Processing of BARs involves a step of collapse of
192 sequences closer than a given edit distance; this process is an additional contributor to collision
193 events. The library complexity sets an upper bound on the number of cells that are needed to generate
194 collisions. The distribution of edit distances in a random set of sequences is modeled after a Gumbel
195 distribution. We estimated the parameters for different barcode lengths and the probability of
196 collisions at $d \leq 3$. The number of sequences, hence the number of edited cells, needed to generate a
197 collision is estimated as in the "Birthday attack" problem and is tabulated in the **Supplementary
198 Table 2** for $d \in \{1, 2, 3\}$.**

199 Regarding the preparation of the BAR-Seq plasmid library, a synthesized single-stranded
200 oligonucleotide (ssODN) library embedding the BAR sequence is amplified by few PCR cycles to
201 generate the complementary strand, digested with the appropriate restriction enzymes and subcloned
202 as insert in the non-barcoded plasmid (**Fig. 2c**). In the single-stranded oligonucleotide, we suggest
203 including stuffer sequences flanking the restriction sites in order to verify for successful digestion of

204 the amplified product. Plasmid amplification is performed by ultra-efficient chemical transformation
205 in recombinase-negative *Escherichia coli*, which are plated on lysogeny broth (LB) agar plates. In
206 parallel, transformation of equimolar amount of dephosphorylated digested backbone ligated in
207 absence of the barcoded insert should be performed as control. The number of colonies in the control
208 plate should be 10^4 -fold lower compared to the one in the other plates **in order to have <1 out of 10^4**
209 **HDR-edited clones being untraceable in the cell population.** An estimation of the total number of
210 colonies provides a useful indication of the library complexity. Colonies are collected and mixed by
211 scraping, and bacteria are grown in LB at 30°C to minimize recombinogenic events. The BAR-Seq
212 plasmid library is purified from the bacteria outgrowth. **Of note, several parameters during BAR-Seq**
213 **library cloning might affect the number of unique BARs and, therefore, can be modified to obtain**
214 **final libraries with higher complexity depending on the experimental needs.** In particular, the number
215 of PCR cycles on the ssODN library can be decreased to improve library diversity. The amount of
216 ligated plasmid, the number of ligation reactions and the number of transformed *E. coli* can be scaled
217 up to achieve BAR-Seq libraries of higher complexity. Electrocompetent rather than chemically
218 competent recombinase-negative cells can be used to further increase final library complexity. High-
219 throughput sequencing of the BAR-Seq plasmid library is highly recommended to assess its diversity
220 (i.e. high complexity and equal representation of the different BARs) before moving to the next steps
221 of the protocol (see also **Box 1 and BAR-Seq bioinformatic analyses**).

222 **Alternatively, generation of the BAR-Seq plasmid library could be also achieved by Gibson**
223 **assembly²⁹, albeit insert >100 bp should be used to maximize its efficiency.** Other detailed protocols
224 have been proposed for the generation of barcoded plasmid libraries².

225
226 **Barcoded viral library production, purification and titration.** The choice of the delivery
227 vehicle for the HDR template is pivotal to maximize efficiency and tolerability of gene editing, and
228 strictly depends on the target cell type and the specific application. **Non-viral delivery methods, such**
229 **as injection, lipofection or nucleofection of plasmids, single- or double-stranded DNA^{30,31}, and viral**
230 **vector transduction, such as IDLV³² or AAV²⁶, can be used to deliver HDR templates into mammalian**
231 **cells.** In our studies, highly efficient gene editing in human HSPCs was achieved by AAV6, which is
232 the most efficient AAV serotype for HSPC transduction¹⁴. BAR-Seq libraries are also compatible
233 with other serotypes depending on the cell types of interest. Briefly, AAV are produced in HEK293
234 adherent mammalian cells by co-transfection of two or three plasmids containing (i) the AAV genes
235 (i.e. *rep* and *cap*), (ii) the essential adenoviral genes VA, E2A and E4, and (iii) the AAV genome
236 with a maximal size of 4.7 kb framed by ITRs required for genome replication and encapsidation³³.
237 **Plasmids required for AAV production are commercially available (e.g. the AAV genome by Agilent**

238 Technologies and the pDGM plasmid for rep-cap and helper expression by Addgene/Russell's lab).
239 Detailed protocol for AAV production, purification and titration, as well as further indications about
240 AAV6 production and their use in *ex vivo* gene editing experiments have been previously
241 published^{26,34,35}. Alternatively, custom AAV can be produced by specialized companies. In general,
242 the experimental workflow and the reagents for production and purification of viral libraries are
243 identical to those of conventional viral vectors. The number of transfected cells during viral library
244 preparation is the most critical parameter to avoid significant loss of library complexity compared to
245 the plasmid library; as a rule of thumb, transfection of 1.1×10^9 HEK293 cells suffices for the
246 production of an AAV library starting from a plasmid library with 10^5 - 10^6 unique BARs³⁵. Scaling
247 up of the AAV production may be necessary for more complex libraries. In any case, diversity
248 assessment of the BAR-Seq viral library by transduction of highly permissive cell lines is highly
249 recommended before moving on to gene editing experiments (see also **Box 2** and **BAR-Seq**
250 **bioinformatic analyses**).

251

252 **Gene editing procedure.** Gene editing protocol varies according to the application and the
253 target cell type. Despite BAR-Seq could be also applied to *in vivo* gene editing, its most
254 straightforward application is in the context of *ex vivo* gene editing for clonal tracking of HDR-edited
255 cells capable of host engraftment. Protocol for the design of CRISPR/Cas gene editing strategies has
256 been previously published³⁶. Here, we briefly report our optimized gene editing procedure for human
257 HSPCs as described in⁹ and suitable for BAR-Seq analyses. HSPCs can be collected from different
258 donor sources, such as cord blood (CB), mobilized peripheral blood (mPB) or bone marrow upon
259 informed consent and in compliance with protocols approved by the relevant Institutional Review
260 Boards. Human HSPCs from these sources can be also purchased from different sellers (e.g. Lonza,
261 STEMCELL Technologies). To favor HDR and maintain long-term repopulating potential, HSPCs
262 are stimulated in culture with early acting cytokines (SCF, FLT3L, TPO, IL6) in the presence of the
263 stem-cell preserving compounds StemRegenin 1 (SR1)³⁷ and UM171^{38,39}. SR1 and UM171 allow
264 more robust hematopoietic output from edited CB HSPCs in hematochimeric mouse models and
265 moderately increase clonality of short-term engrafting progenitors⁹. After 3 days of stimulation,
266 CRISPR/Cas nucleases are delivered by nucleofection as ribonucleoproteins (RNPs) composed by
267 the purified Cas protein and the single guide RNA (sgRNA) synthesized with chemical modifications
268 to stabilize its structure and avoid innate cellular responses impacting on cell biology^{9,19}.
269 Alternatively, ZFNs, TALENs and CRISPR/Cas can be delivered as HPLC purified mRNA^{19,39-41}.
270 Nucleofection can be also exploited to co-deliver barcoded HDR templates, such as dsDNA⁴² or
271 ssDNA⁴³, or editing enhancers⁹. When using AAV6 for the delivery of barcoded HDR template,

272 HSPCs are transduced immediately after nucleofection¹⁴. Alternative protocols for AAV6 or IDLV-
273 based gene editing in HSPCs were previously described^{9,26,44}. Human edited HSPCs can then be
274 transplanted by tail-vein injection in immunodeficient mice (NSG or NSGW41) to evaluate their
275 long-term repopulating and self-renewal potential. We suggest transplanting the same number of
276 culture-initiating HSPCs/mouse (i.e. the outgrowth of the same number of starting cells at the
277 beginning of the culture) across experimental conditions, rather than the same number of HSPCs after
278 editing. This procedure allows to stringently compare the impact of different editing treatments on
279 HSPC repopulation capacity. Of note, transplantation of high number culture-initiating
280 HSPCs/mouse may lead to saturation of the hematopoietic niche⁹ and may camouflage differences of
281 HSPC reconstitution capacity across experimental conditions. We suggest transplanting $1.0-1.5 \times 10^5$
282 and $<5 \times 10^5$ culture-initiating cells/mouse when editing CB or mPB HSPCs, respectively.

283 Quantification of the editing efficiency and phenotypic characterization of the edited cell
284 population (either *ex vivo* or *in vivo*) might be highly relevant to complement and interpret BAR-Seq
285 data. If reporter genes (e.g. NGFR, GFP) are embedded in the barcoded HDR template, the percentage
286 of reporter-expressing cells can be used as readout of the fraction of cells harboring integration. For
287 more reliable quantification it is advisable to measure reporter expression in the treated cells after
288 several days of culture, when multiple rounds of proliferation have diluted any residual episomal
289 HDR template, which may otherwise contribute to reporter expression and confound the assessment
290 of integrated copies. To measure HDR efficiency at molecular level, we perform digital droplet PCR
291 (ddPCR)-based assays that quantify the copies of edited alleles and those of a reference unedited
292 gene^{39,42}. We advise to design the ddPCR amplicon following an “In-Out” PCR approach in order to
293 specifically amplify the donor-genome junction (either 5’ or 3’) upon on-target HDR-mediated
294 integration (**Fig. 2b**). Although these assays must be designed and optimized for each editing strategy,
295 their high sensitivity and precision allows reliable quantification of HDR editing events. Notably, the
296 ddPCR amplicon can be designed to overlap with the BAR-Seq amplicon, whenever possible. If
297 clonal tracking studies are also extended to NHEJ-edited cells, accurate quantification of the indels
298 frequency is directly provided by targeted NGS of the nuclease target site⁴⁵. Alternatively, mismatch-
299 sensitive endonuclease assay or Sanger sequencing followed by deconvolution analysis (e.g. TIDE)⁴⁶
300 may be performed to assess the overall nuclease cutting efficiency. Independently of the method used
301 for the assessment of editing efficiency, we recommend including adequate controls in the
302 experimental design (i.e. HDR donor only, untreated cells) and performing HDR-editing analyses >3
303 days after editing procedure, if applicable, to minimize any confounding effect due to the presence
304 of episomal HDR template (e.g. PCR jumping).

305

306 **BAR-Seq amplicon design and library preparation.** BARs are retrieved from the BAR-Seq
307 plasmid/viral library, when assessing its complexity and diversity, or genomic DNA (gDNA) of
308 edited cells.

309 In the first case, BAR sequences can be extracted by PCR amplification using primers flanking
310 the BAR. To ensure an adequate coverage of the original library, the number of sequencing reads
311 should be set at least 10-fold higher than the expected library complexity, as estimated by the total
312 number of bacterial colonies counted. Amplicons can be sequenced by single-end Illumina MiSeq
313 (MiSeq™ Reagent Kit v3), NextSeq or HiSeq platforms, depending on the required number of reads.
314 Consecutive sequencing rounds of the same library can be performed to increase sequencing depth
315 when an insufficient number of reads has been obtained.

316 In the second case, the number of cells used for the analysis depends on the expected
317 complexity of the population of interest and the percentage of HDR-edited cells: the higher is the
318 expected population complexity, the higher is the number of HDR-edited cells to be harvested and
319 analyzed by BAR-Seq to exhaustively investigate cell population complexity. From another
320 perspective, the number of HDR-edited cells analyzed determines the abundance of the rarest BAR
321 (i.e. cell clone) that can be identified. As a rule of thumb, clones representing 0.01% of an HDR-
322 edited cell fraction, whose proportion is 10% of the bulk population, can be recovered only if
323 analyzing at least 100,000 bulk cells. As also indicated in other clonal tracking pipelines², we suggest
324 performing BAR-Seq analysis on 10-fold higher number of bulk cells to ensure better results.
325 Importantly, sorting of reporter-expressing cells, if applicable, as *bona-fide* HDR-edited cells is not
326 required since the BAR-Seq amplicon design allows to extract BARs from a bulk population.

327 In our work, we performed BAR-Seq analyses on *in vitro* cultured samples of edited HSPCs,
328 on whole blood samples collected at different times after transplant and on sorted human cell lineages
329 (B cells, myeloid cells, T cells, HSPCs) from hematopoietic organs of reconstituted NSG mice (either
330 primary or secondary recipients)⁹. When analyzing blood samples or sorted cell lineages, it should be
331 noted that the number of HDR-edited cells within the harvested bulk population might sometimes be
332 low due to poor human cell engraftment, limited lineage output or low biological material. The BAR-
333 Seq wet procedure and bioinformatic analysis successfully extracted BARs from a bulk population
334 comprising as few as 100 HDR-edited cells. However, such a low number of cells may call for caution
335 when interpreting this data since rare clones with <1% abundance may be undetectable. Based on our
336 findings on the frequency of repopulating cells⁹, collection of >10,000 bulk cells from sorted cell
337 lineages should be set as threshold to obtain robust results even with as low as 1% HDR editing in
338 the human graft.

339 In any case, equivalent amounts of gDNA should be used among different samples for library
340 preparation to avoid biasing BAR-Seq analysis. BAR sequences can be extracted by PCR
341 amplification. To minimize sequencing errors in the BAR region, we suggest designing asymmetric
342 amplicons with the forward primer (Read 1, R1) binding close to the BAR sequence. Amplicon length
343 can vary based on the position of the BAR in the HDR template. We usually design amplicons
344 spanning a region of 300-400 bp to minimize carryover of primer and primer dimers during amplicon
345 purification. BAR-Seq amplicon preparation is based on two PCR rounds of maximum 15-20 cycles
346 each. In the first round, the BAR-containing region is amplified with a couple of “PCR1” primers
347 designed to bind the target site (**Supplementary Table 3**). **Of note, PCR1 primers and amplification**
348 **conditions must be optimized for each target site of interest, which may introduce variability in**
349 **amplification efficiency or sensitivity across different loci.** In the second round, R1/R2 primer
350 complementary sequences, i5/i7 Illumina indexes and P5/P7 are added to the amplicon by nested
351 PCR using “PCR2” primers listed in **Supplementary Table 3**. Single-round PCR using only “PCR2”
352 primers may be considered as an option for BAR extraction, although lower amplification efficiency
353 may occur when performing BAR-Seq on few edited cells. We multiplexed up to 49 independent
354 samples in the same Illumina sequencing run (for MiSeq: Reagent Kit v3). **During amplicon**
355 **preparation and sequencing, we suggest including one sample in which no BAR should be retrieved**
356 **by the BAR-Seq bioinformatic analysis. This additional control may be helpful to evaluate the**
357 **background sequencing noise, the presence of cross-contaminations and the extent of index**
358 **switching.** Higher or lower level of multiplexing are possible depending on the desired sequencing
359 depth for each sample. Sequencing read length may vary according to the position of the BAR within
360 the amplicon. **Although in our key reference paper we performed paired-end sequencing (in which**
361 **we discarded the R2 file because only the R1 reads contained the amplicon), single-end Illumina**
362 **MiSeq, NextSeq or HiSeq sequencing is sufficient since the bioinformatic pipeline works with only**
363 **one fastq file for each sample. In fact, the only requirement is that the amplicons containing the BARs**
364 **are fully contained in the sequencing reads provided to the pipeline. In case the full amplicon is too**
365 **long to be fully contained in a single Illumina read, paired-end sequencing can be performed so that**
366 **both reads will cover the BAR sequence. In this case we suggest performing a read merging using**
367 **FLASH⁴⁷, which is a software specifically designed to merge pairs of reads when the original DNA**
368 **fragments are shorter than twice the length of reads. The resulting longer reads can be then provided**
369 **to the BAR-Seq pipeline.**

370 **Importantly, also sequencing depth strictly depends on the number of edited cells analyzed.**
371 **In agreement with other protocols², we advise sequencing about 100 reads for each HDR-edited cell**
372 **and we recommend avoiding massive over- or under-sequencing of the samples, which may increase**

373 the background noise or may miss some clones, respectively. When applied to clonal tracking of gene
374 edited HSPCs *in vivo*, from 50,000 to 500,000 reads for each sample are sufficient (considering the
375 average HDR editing efficiency and the advised number of cells to collect). Replicates of sample
376 library preparation and sequencing are typically not necessary but may be relevant when analyzing
377 samples with low input gDNA in order to minimize sampling issues.

378

379 **BAR-Seq bioinformatic analysis.** The BAR-Seq bioinformatic pipeline is freely available at
380 <https://bitbucket.org/bereste/bar-seq>. After download and installation of the required software and
381 packages, the pipeline can be executed locally (**Figure 3**).

382 As in the majority of the NGS reads analyses, the first bioinformatic operations to be
383 performed are quality check, quality filtering and trimming (if needed) of input sequences. As first
384 goal, the BAR-Seq bioinformatic pipeline extracts BARs from sequencing reads by exploiting the
385 amplicon structure, i.e. the known conserved sequences flanking the BAR (upstream and
386 downstream). BAR-Seq uses TagDust2⁴⁸ to process the input reads and extract BAR sequences, since
387 its Hidden Markov Model (HMM) for complex sequence structures, which include gaps and partial
388 blocks, provides good flexibility in the detection of anchor sequences (provided as input) used to
389 identify the BAR, even in presence of errors in the sequences around the BAR. The HMM-based
390 approach implemented in TagDust2 is quite helpful to retrieve BARs from reads in which sequencing
391 errors in the known amplicon sequences adjacent to the BAR are present. To balance this flexibility,
392 we imposed an additional filter based on the barcode structure and its length (see **Design and
393 production of the barcoded plasmid library** section) to discard all the extracted BARs not
394 satisfying these constraints. Although by default our pipeline relies on TagDust2, any bioinformatic
395 tool able to identify unknown substrings of variable length by exploiting the known adjacent ones,
396 possibly containing mismatches or small insertions/deletions, can be used to accomplish this task. A
397 notable example of such applications is the R package *genBaRcode*, which allows to digest
398 sequencing reads with many different error-correction approaches and visualization routines⁴⁹.
399 Anyway, as a final result of this step, the preliminary set of BARs is extracted from the input
400 sequences and their abundance is computed by counting the number of occurrences.

401 Since BARs extracted with TugDust2 could have different lengths due to its flexibility, a
402 preliminary filter based on sequence length distribution estimates the most recurring BAR length
403 value and keeps only those BARs having that length, while discarding those too long or too short.
404 Moreover, the BAR-Seq pipeline offers the possibility to apply or not additional structural filters. In
405 the former case, the user has to possibility to filter out: i) sequences having in at least one position a

406 nucleotide with frequency below 1%, assuming that a nucleotide with such a low nucleotide
407 abundance is artifactual, or ii) BARs not respecting a fixed structure (expressed in IUPAC code).

408 However, the number and the counts of this preliminary set of BARs could be influenced by
409 errors occurring during the sequencing process. Indeed, sequencing errors could produce low count
410 spurious BARs bearing sequence similarity with the much more abundant ones. To account for such
411 issue, we developed a graph-based method which identifies and then merges “ego-networks” for each
412 independent sample to obtain a refined set of BARs. Briefly, a graph is built from the pairwise
413 Levenshtein distance d between BARs, including only edges having d lower than a defined threshold
414 t ($d \leq 3$ in our experiments). While higher thresholds tend to produce spurious results and merge
415 unrelated sequences, the appropriate value t may depend on BAR length. An ego-network is created
416 for each node, i.e. a subgraph where the BAR of interest (the “focal” node) is connected to related
417 sequences (the “alters”) having $d \leq t$ by definition. Each ego-network is then collapsed to the focal
418 node and the alters are removed from the graph. This process is performed iteratively on all BARs
419 ranked in descending abundance. Importantly, this approach does not build shared “ego-networks”
420 across samples, even when providing multiple samples at once. Of note, we avoided to use a
421 predefined list of known sequences (“whitelist”) for the extraction of BARs because it would require
422 nearly exhaustive sequencing of the original plasmid/viral library and likely multiple rounds of library
423 sequencing to minimize the loss of real BARs and the inclusion of artifactual BARs in the whitelist,
424 respectively. Indeed, an incomplete whitelist may compromise the next step of the BAR-Seq analysis
425 by dropping out real barcodes (and therefore clones) and underestimating cell population complexity.

426 Optionally, further filtering can be applied to this refined set of BARs by discarding those
427 having read count lower than a selected threshold c ($c < 3$ in our experiments⁹). This filtering might
428 be useful to take into account background sequencing noise. To verify the need of this threshold and
429 estimate the appropriate value c , we strongly suggest including in the sequencing run a control
430 amplicon derived from cells edited with the conventional non-barcoded HDR template, where no
431 BAR should be retrieved. After filtering, the remaining BARs can be identified as the set of valid
432 BARs. To verify that this set of BARs is informative, we improved the approach previously described
433 to estimate the level of richness for each sample^{9,50}. Briefly, the richness is defined as the ratio
434 between the number of observed BARs and the Chao1 abundance-based index, corrected to take into
435 account the minimum count threshold c . Optimal experiments should achieve high richness values
436 ($R > 0.7$), while low richness levels ($R < 0.3$) could indicate poor sequencing depth. In this case, the
437 amplicon preparation or sequencing process must be retried following our **Troubleshooting** guide.
438 Moreover, we provided additional metrics to better describe the sample complexity: Effective
439 Number of Species (ENS) and Equitability²⁸.

440 Since most studies are focused on highly abundant clones more robustly contributing to the
441 cell population output, BAR-Seq gives to possibility to identify and select the (sub)set of “dominant”
442 BARs. Valid sequences are ranked from the most to the least abundant and a saturation-based
443 approach is applied. The dominant set is defined as the pool of BARs representing more than a chosen
444 ratio of the total abundance, while the remaining BARs are considered as “rare”. The user can select
445 the value for the identification of dominant BARs based on their distribution. In our BAR-Seq
446 analyses on repopulating edited cells in xenotransplanted hosts, we set this value to 90 or 95%⁹.

447 When analyzing more samples, BAR sharing (i.e. the abundance of each valid sequence in all
448 samples) can be computed. BAR sharing is reported in tabular form with valid BARs as rows and
449 samples as columns, which gives the possibility to check for contaminations among samples or
450 longitudinal BAR tracking within the same experimental condition.

451 To facilitate the analyses, we developed a user-friendly web-application available at
452 <http://www.bioinfotiget.it/barseq>, which can perform the whole pipeline remotely upon the upload of
453 the input sequencing files and the description of the amplicon structure by specifying the conserved
454 sequences flanking the BAR (upstream and downstream) (**Figure 4**). In the home page of this online
455 tool, the user can customize the aforementioned thresholds and values for background sequencing
456 noise and dominant BARs identification. **Further parameters can be customized by clicking on the**
457 **“Advanced Options” button**. It must be noticed that the application requires that all the pre-processing
458 steps, like quality filtering or trimming of the input sequences, are performed prior to the upload. The
459 pipeline runs on a dedicated server and results are stored for 48 hours. Results are available for
460 visualization and download using the provided link. **Moreover, an email notification is sent to the**
461 **user when the analyses are finished**. For each submitted sample, the result page presents a report of
462 the sequencing run with the number of successfully or unsuccessfully extracted BARs and the
463 statistics about each step of the BAR-Seq pipeline. Moreover, the set of valid BARs as well as the
464 dominant ones are shown and can be downloaded as text files (“Download Full/Selected Barcode
465 Results”). Plots showing BAR structures and saturation curves can be downloaded as images (.png
466 format) by clicking on them. Additionally, when providing multiple samples, the sharing of valid and
467 dominant BARs is computed and available in tabular form as well as heatmap (“Shared Results”).
468 **Sample diversity and richness can be automatically measured with three different indexes (ENS,**
469 **Equitability and Chao1 abundance-based index) by clicking on the “Check Diversity/Richness”**
470 **button in the “Results” page. Alternatively, the same operation can be done manually by downloading**
471 **the text file from the “Results” page and uploading it in the “Check Diversity/Richness” tab.**

472 Of note, when analyzing the original plasmid/viral library, the latter BAR-Seq web-
473 application function allows to estimate the number of uniquely labeled cells that can be tracked with

474 a certain confidence level by using the given library (as shown in the resulting table). Two more tabs
475 are available on the website: “Help” for more details concerning the use of the different web tools
476 with related examples to test their functionality; “Contacts” for reporting any issue related to the use
477 of the web application.

478

479 **LIMITATIONS**

480 The efficiency of HDR may limit BAR-Seq application particularly in slowly cycling or
481 quiescent cells. HDR editing also requires extensive manipulation (DNA DSB and simultaneous
482 delivery of the DNA template), which might cumulatively impact on cell survival and proliferation.
483 These limitations, however, pertain to the biology of target cells and their suitability for templated
484 editing and not to the tracking technology *per se*. Several strategies to enhance HDR editing have
485 been proposed so far¹³. In our study we found that transient hyperactivation of the E2F pathway and
486 simultaneous dampening of the editing-induced p53-mediated response increase the permissiveness
487 to HDR in long-term repopulating HSPCs and improve the tolerability of the editing procedure^{9,42}.

488 Although the frequency of biallelic HDR targeting is generally low, a fraction of edited cell
489 clones may carry two BARs if targeting somatic chromosomes. Such multiple BAR integrations
490 might have minimal influence on data interpretation when interrogating cell fate and clonal
491 composition²⁷. Editing of sex-linked chromosomes in male cells allows more accurate quantification
492 of the clonal composition.

493 BAR-Seq does not provide information on the dynamics and clonality of unedited or NHEJ-
494 edited cells, which may be present in indifferent proportions in a cell population treated for HDR-
495 editing. In our study, we combined BAR-Seq and CRISPResso2⁴⁵ pipelines to comprehensively
496 analyze clonal behavior of HDR- and NHEJ- edited cells⁹. Finally, detection of rare quiescent or
497 short-living cells that provide very limited cell output in transplantation experiments might be
498 challenging with the BAR-Seq pipeline due to their low abundance close to sequencing background
499 noise.

500 Low sequencing depth may result in an under-sampling of the overall population of cells (and,
501 consequently, of BARs) in the sample, limiting the overall BAR-Seq procedure. In this conditions,
502 detection of low abundant BARs might be challenging, especially when analyzing highly polyclonal
503 populations.

504

505 **MATERIALS**

506 1.1. REAGENTS

507 **Barcoded HDR plasmid cloning**

- 508 ▪ HPLC purified single-stranded oligodeoxynucleotide (ODN) containing the degenerated
509 BAR sequence, the stuffer sequences and the restriction site as in **Fig. 2c** (Sigma-Aldrich, or
510 another vendor); an example of the BAR ssODN is provided in **Supplementary Table 3**
511 ▪ Non-barcoded plasmid template (custom). **Synthesis of the non-barcoded HDR template and**
512 **subcloning can be performed by gene synthesis services (GenScript; or another vendor).**
513 **Plasmid backbones suitable for subcloning are any transfectable plasmid (e.g. pUC19),**
514 **pAAV-MCS (Agilent; cat no. 240071) or pCCL-LV (available under Material Transfer**
515 **Agreement with Ospedale San Raffaele/Telethon, Luigi Naldini's lab)**
- 516 ▪ Bsu36I restriction enzyme (New England Biolabs, cat. no. R0524S)
517 ▪ SphI-HF® restriction enzyme (New England Biolabs, cat. no. R3182S)
518 ▪ CutSmart® buffer (New England Biolabs, cat. no. B7204S; typically provided with
519 restriction enzymes)
520 ▪ SeaKem® GTG® Agarose (Lonza, cat. no. 50070)
521 ▪ Gel Loading Dye, Purple (New England Biolabs, cat. no. B7024S)
522 ▪ 1 kb DNA Ladder (New England Biolabs, cat. no. N3232S)
523 ▪ Atlas ClearSight DNA Stain (Bioatlas, cat. no. BH40501)
524 ▪ NucleoSpin® Gel and PCR Clean-up (Machery-Nagel, cat. no. 740609.250S)
525 ▪ Easy-A High-Fidelity PCR Master Mix (Agilent Technologies, cat. no. 600640)
526 ▪ Primers (Sigma-Aldrich or another vendor; see **Supplementary Table 3** for ordering
527 details)
528 ▪ MinElute PCR Purification Kit (Qiagen, cat. no. 28004)
529 ▪ QIAquick PCR Purification Kit (Qiagen, cat. no. 28104)
530 ▪ TAE (50x concentrate) pH8.0 (VWR, cat. no. 444125D)
531 ▪ Antarctic Phosphates (New England Biolabs, cat. no. M0289L)
532 ▪ T4 DNA Ligase (New England Biolabs, cat. no. M0202L)
533 ▪ High Sensitivity D1000 ScreenTape (Agilent Technologies, cat. no. 5067-5585)
534 ▪ High Sensitivity D1000 Reagents (Agilent Technologies, cat. no. 5067-5584)
535 ▪ XL10-Gold Ultracompetent Cells (Agilent Technologies, cat. no. 200315)
536 ▪ Nuclease-free Water for Molecular Biology (Sigma-Aldrich, W4502-1L)
537 ▪ S.O.C. Medium (Invitrogen, cat. no. 15544034)
538 ▪ LB Broth (ThermoFisher, cat. no. 10855001)
539 ▪ Ampicillin (Sigma-Aldrich, cat. no. 10835242001) or another antibiotic accordingly to
540 plasmid resistance.
541 ▪ 150 mm LB Agar Plates with 100 µg/ml Ampicillin (VWR; cat. no. 100217-214)

542 ▪ NucleoBond Xtra Maxi EF (Machery Nagel, cat. no. 740424.50)

543

544 **Ex-vivo culture of human HSPCs**

545 ▪ Iscove's DMEM, 1X (Corning, cat. no. 10-016-CV)

546 ▪ FetalClone® II (HyClone™, cat. no. SH30066.03)

547 ▪ DPBS without Ca²⁺ and Mg²⁺, 1X (Corning, cat. no. 21-031-CV)

548 ▪ ACK lysing buffer (Gibco, cat. no. A10492-01)

549 ▪ StemSpan SFEM (StemCell Technologies, cat. no. 09650)

550 ▪ Penicillin – Streptomycin (Lonza, cat. no. DE17-602E)

551 ▪ L-Glutamine (Lonza, cat. no. 17-605E)

552 ▪ Recombinant human SCF (PeproTech, cat. no. 300-07)

553 ▪ Recombinant human Flt3-L (PeproTech, cat. no. 300-19)

554 ▪ Recombinant human TPO (PeproTech, cat. no. 300-18)

555 ▪ Recombinant human IL-6 (PeproTech, cat. no. 200-06)

556 ▪ 16,16-dimethyl prostaglandin E2 - PGE₂ (Cayman, cat. no. 14750).

557 ▪ StemRegenin 1 - SR1 (Biovision, cat. no. 1967)

558 ▪ UM171 (StemCell Technologies, cat. no. 72914)

559

560 **Gene editing of human HSPCs**

561 Synthetic chemically modified guide RNAs (2 part):

562 ▪ Alt-R® CRISPR-Cas9 tracrRNA, 100 nmol (IDT, cat. no. 1072534)

563 ▪ Alt-R CRISPR-Cas9 crRNA, 10 nmol (IDT, custom)

564 CRITICAL STEP – Alternatively, single gRNAs (Synthego, custom; or another vendor) can be
565 used.

566 ▪ Alt-R® Cas9 Electroporation Enhancer, 10 nmol (IDT, cat. no. 1075916)

567 ▪ sNLS-SpCas9-sNLS Nuclease (Aldevron, cat. no. 9212-5MG)

568 ▪ P3 Primary Cell 4D-Nucleofector™ X Kit S (Lonza, cat. no. V4XP-3032)

569 ▪ DPBS, 1x without calcium and magnesium (Corning, cat. no. 21-031-CV)

570

571 **Xenotransplantation of edited HSPCs**

572 ▪ DPBS, 1x without calcium and magnesium (Corning, cat. no. 21-031-CV)

573

574 **In-vivo phenotyping of human edited lineages (GFP compatible)**

575 ▪ 0.5 M EDTA, pH 8.0 (Invitrogen, cat. no. 15575-038) > dilution 1:3 in PBS

576 ▪ SPHERO™ Rainbow Calibration Particles (Spherotech, cat. no. RCP-30-5A)

- 577 ▪ BD FACS™ Accudrop beads (BD; cat. no. 345249)

578

579 **Antibodies for peripheral blood and spleen phenotyping**

- 580 ▪ Anti-human CD45-PB, Clone HI30 (BioLegend, cat. no. 304029, RRID: AB_2174123)
581 https://scicrunch.org/resolver/RRID:AB_2174123
- 582 ▪ Anti-human CD19-PE, Clone SJ25C1 (BD Biosciences, cat. no. 345789, RRID:
583 AB_2868815) https://scicrunch.org/resolver/RRID:AB_2868815
- 584 ▪ Anti-human CD13-APC, Clone WM15 (BD Biosciences, cat. no. 557454, RRID:
585 AB_398624) https://scicrunch.org/resolver/RRID:AB_398624
- 586 ▪ Anti-human CD3-PE-Cy7, Clone HIT3a (BioLegend, cat. no. 300316, RRID: AB_314052)
587 https://scicrunch.org/resolver/RRID:AB_314052
- 588 ▪ Anti-human CD8-APC-H7, Clone Sk1 (BD Biosciences, cat. no. 641400, RRID:
589 AB_1645736) https://scicrunch.org/resolver/RRID:AB_1645736
- 590 ▪ 7-AAD Viability Staining Solution (BioLegend, cat. no. 420404)

591

592 **Antibodies for bone marrow phenotyping**

- 593 ▪ Anti-human CD45-APC-H7, Clone 2D1 (BD Biosciences, cat. no. 348815, RRID:
594 AB_2868859) https://scicrunch.org/resolver/RRID:AB_2868859
- 595 ▪ Anti-human CD34-PE-Cy7, Clone 8G12 (BD Biosciences, cat. no. 348811, RRID:
596 AB_2868855) https://scicrunch.org/resolver/RRID:AB_2868855
- 597 ▪ Anti-human CD19-PE, Clone SJ25C1 (BD Biosciences, cat. no. 345789, RRID:
598 AB_2868815) https://scicrunch.org/resolver/RRID:AB_2868815
- 599 ▪ Anti-human CD33-VioBlue, Clone AC104.3E3 (Miltenyi Biotec, cat. no. 130-099-485,
600 RRID: AB_2660351) https://scicrunch.org/resolver/RRID:AB_2660351
- 601 ▪ Anti-human CD3-APC, Clone UCHT1 (BD Biosciences, cat. no. 555335, RRID:
602 AB_398591) https://scicrunch.org/resolver/RRID:AB_398591
- 603 ▪ 7-AAD Viability Staining Solution (BioLegend, cat. no. 420404)

604

605 **BAR-Seq library preparation and quantification**

- 606 ▪ QIAamp DNA Micro Kit (Qiagen, cat. no. 56304)
- 607 ▪ Primers (Sigma-Aldrich, Metabion or another vendor; see **Supplementary Table 3** for
608 ordering details)
- 609 ▪ GoTaq® G2 DNA Polymerase (Promega, cat. no. M7841) or Pfu DNA Polymerase
610 (Promega, cat. no. M7741)

- 611 ▪ Nuclease-free Water for Molecular Biology (Sigma-Aldrich, W4502-1L)
- 612 ▪ dNTP Mix (Promega, cat. no. U1515)
- 613 ▪ AmpPure XP (Beckman Coulter, cat. no. A63881)
- 614 ▪ High Sensitivity D1000 ScreenTape (Agilent Technologies, cat. no. 5067-5585)
- 615 ▪ High Sensitivity D1000 Reagents (Agilent Technologies, cat. no. 5067-5584)

616

617 **Illumina sequencing**

- 618 ▪ PhiX control V3 (Illumina, cat. no. FC-110-3001)
- 619 ▪ MiSeq™ Reagent Kit v3 (150-cycle) (Illumina, cat. no. MS-102-3001) or NextSeq 500/550
- 620 High Output Kit v2.5 (150 Cycles) (Illumina, cat. no. 20024907)

621

622 **1.2. BIOLOGICAL MATERIAL**

- 623 ▪ Frozen CB-derived CD34⁺ human HSPCs (Lonza, cat. no. 2C-101; or another vendor).
- 624 ! CAUTION – *The use of human material must be approved by local institution and*
- 625 *authorities.*
- 626 ▪ NOD.Cg-Prkdc^{SCID} Il2rg^{tm1Wjl/SzJ} (NSG) female mice (Charles River, cat. no. NSG614)
- 627 ! CAUTION – *The use of animal models must be approved by local institution and authorities*
- 628 *in agreement with law.*

629

630 **1.3. EQUIPMENT**

631 1.3.1. Experimental part

- 632 ▪ Pipet-Lite LTS Pipette L-1000XLS+ (Rainin, cat. no. 17014382)
- 633 ▪ Pipet-Lite LTS Pipette L-200XLS+ (Rainin, cat. no. 17014391)
- 634 ▪ Pipet-Lite LTS Pipette L-20XLS+ (Rainin, cat. no. 17014392)
- 635 ▪ Pipet-Lite LTS Pipette L-10XLS+ (Rainin, cat. no. 17014388)
- 636 ▪ Pipet-Lite XLS+ Multichannel Pipette 8ch/10 µL (Rainin, cat. no. 17013802)
- 637 ▪ Pipet-Lite XLS+ Multichannel Pipette 8ch/20 µL (Rainin, cat. no. 17013803)
- 638 ▪ Pipet-Lite XLS+ Multichannel Pipette 8ch/200 µL (Rainin, cat. no. 17013805)
- 639 ▪ Pipette Tips RT UNV 10µL FGL 960A/10 (Rainin, cat. no. 30389176)
- 640 ▪ Pipette Tips RT LTS 20µL FL 960A/10 (Rainin, cat. no. 30389226)
- 641 ▪ Pipette Tips RT LTS 200µL FLW 960A/10 (Rainin, cat. no. 30389241)
- 642 ▪ ART 10 Pipette Tips (Carlo Erba Reagents, cat. no. FL9214000)
- 643 ▪ ART 20P Pipette Tips (Carlo Erba Reagents, cat. no. FL92149P0)
- 644 ▪ ART 200 Pipette Tips (Carlo Erba Reagents, cat. no. FL9206900)

- 645 ▪ ART 1000 Pipette Tips (Carlo Erba Reagents, cat. no. FL92079E0)
- 646 ▪ SWIFTPET PRO (HTL, cat. no. 0390)
- 647 ▪ Falcon® 2 mL Serological Pipet (Corning, cat. no. 357507)
- 648 ▪ Falcon® 5 mL Serological Pipet (Corning, cat. no. 357543)
- 649 ▪ Falcon® 10 mL Serological Pipet (Corning, cat. no. 357551)
- 650 ▪ Falcon® 25 mL Serological Pipet (Corning, cat. no. 357525)
- 651 ▪ Falcon® 96-well Clear Microplate (Corning, cat. no. 353072)
- 652 ▪ Costar® 48-well Clear TC-treated Multiple Well Plates (Corning, cat. no. 3548)
- 653 ▪ Falcon® 24-well Clear Flat Bottom TC-treated Polystyrene Multiwell Cell Culture Plate
654 (Corning, cat. no. 353047)
- 655 ▪ Falcon® 6-well Clear Multiwell Plate (Corning, cat. no. 353046)
- 656 ▪ Nunclon™ Delta Surface 12-well Plate (Thermo Fisher Scientific, cat. no. 150628)
- 657 ▪ 1000 µL Filtered tips for pipettes (Thermo Fisher Scientific, cat. no. FL92079E0)
- 658 ▪ 200 µL Filtered tips for pipettes (Thermo Fisher Scientific, cat. no. FL9206900)
- 659 ▪ 20 µL Filtered tips for pipettes (Thermo Fisher Scientific, cat. no. FL92149P0)
- 660 ▪ 10 µL Filtered tips for pipettes (Thermo Fisher Scientific, cat. no. FL9214000)
- 661 ▪ Thermowell® Tube Strip (Corning, cat. no. 6542)
- 662 ▪ Eppendorf Safe-Lock tubes, 0.5 mL (Eppendorf, cat. no. 0030121023)
- 663 ▪ Eppendorf Safe-Lock tubes, 1.5 mL (Eppendorf, cat. no. 0030120086)
- 664 ▪ DNA LoBind Tubes, 1.5 mL (Eppendorf, cat. no. 0030108051)
- 665 ▪ DNA LoBind Tubes, 2.0 mL (Eppendorf, cat. no. 0030108078)
- 666 ▪ Eppendorf twin.tec® PCR plate 96 LoBind (Eppendorf, cat. no. 0030129504)
- 667 ▪ Falcon™ 50mL Conical Centrifuge Tubes (Fisher Scientific, cat. no. 14-432-22)
- 668 ▪ Falcon™ 15mL Conical Centrifuge Tubes (Fisher Scientific, cat. no. 11507411)
- 669 ▪ Falcon™ Round-Bottom Polystyrene Test Tubes with Cell Strainer Snap Cap (Fisher
670 Scientific, cat. no. 08-771-23)
- 671 ▪ L-Shape Cell Spreader (VWR; cat. no. 76207-748)
- 672 ▪ IKA® Vortex Genius 3 (IKA, cat. no. 00033400009)
- 673 ▪ IKA® MS3 basic (IKA, cat. no. 0003617000)
- 674 ▪ ThermoMixer® C (Eppendorf, cat. no. 5382000015)
- 675 ▪ Centrifuge 5430 (Eppendorf, cat. no. 5427000415)
- 676 ▪ Centrifuge 5810R (Eppendorf, cat. no. 5811000620)
- 677 ▪ Disposable scalpel, stainless steel blade no. 11 (VWR, cat. no. 1110811)
- 678 ▪ T100™ Thermal Cycler (Bio-Rad, cat. no. 1861096)

- 679 ▪ Heracell™ 150i CO₂ Incubator (Thermo Fisher Scientific, cat. no. 50116048)
- 680 ▪ New Brunswick™ Innova® 42 (Eppendorf, cat. no. M1335-0012)
- 681 ▪ Nanodrop™ 8000 Spectrophotometer (Thermo Fisher Scientific, cat. no. ND-8000-GL)
- 682 ▪ Eppendorf Biophotometer® D30 (Eppendorf, cat. no. 6133000001)
- 683 ▪ PowerPac™ Basic Power Supply (Bio-Rad, cat. no. 1645050)
- 684 ▪ Sub-Cell® GT Gel Tray (Bio-Rad, cat. no. 1704416)
- 685 ▪ Sub-Cell® GT Comb 10-well (Bio-Rad, cat. no. 170444)
- 686 ▪ Wide Mini-Sub Cell® GT Horizontal Electrophoresis System (Bio-Rad, cat. no.
- 687 1704468)
- 688 ▪ Analytical Balance ME54T/00 (Mettler Toledo, cat. no. 30216540)
- 689 ▪ Molecular Imager® Gel Doc™ XR System (Bio-Rad, cat. no. 1708195EDU)
- 690 ▪ QUICKSPIN2 Mini-Centrifuge (Clever Scientific, cat. no. 5055323269776)
- 691 ▪ Agilent 4200 TapeStation System (Agilent Technologies, cat. no. G2991AA)
- 692 ▪ Loading Tips (Agilent Technologies, cat. no. 5067-5599)
- 693 ▪ Pierceable Foil Heat Seal for PCR applications (Bio-Rad, cat. no. 1814040)
- 694 ▪ 4D-Nucleofector™ Core Unit (Lonza, cat. no. AAF-1002B)
- 695 ▪ 4D-Nucleofector™ Core Unit (Lonza, cat. no. AAF-1002X)
- 696 ▪ Falcon® 40 µM Cell Strainer (Corning, cat. no. 352340)
- 697 ▪ Falcon® 5 mL Round Bottom Polystyrene Test Tube with Cell Strainer Snap Cap
- 698 (Corning, cat. no. 352235)
- 699 ▪ BD FACSAria Fusion (BD, cat. no. special order)
- 700 ▪ BD FACSCanto II (BD, cat. no. special order)
- 701 ▪ FCS Express 6 Flow (De Novo Software, <https://denovosoftware.com/purchasing>)
- 702 ▪ DynaMag™ 96 Side Skirted Magnet (Thermo Fisher Scientific, cat. no. 12027)
- 703 ▪ TQ-Prep™ Workstation (Beckman Coulter, cat. no. 6605429)
- 704 ▪ IMMUNOPREP Reagent System (Beckman Coulter, cat. no. 7546999)
- 705 ▪ TC20™ Automated Cell Counter (Bio-Rad, cat. no. 1450102)
- 706 ▪ Cell Counting Kit (Bio-Rad, cat. no. 1450003)
- 707 ▪ RS-2000 X-ray Irradiator (Rad Source, cat. no. special order)
- 708 ▪ PX1 PCR Plate Sealer (Bio-Rad, cat. no. 1814000)
- 709 ▪ Microvette® 500 K3E (Sarstedt, cat. no. 20.1341)
- 710 ▪ BD Micro-Fine+ 0.5 ml U-100 insulin syringe (BD, cat. no. 324892)

711

712 1.3.2. Computational part

- 713 ▪ The pre-processing of sequences can be performed on a computer running the Linux
714 terminal (also called command line interface or shell), with installed common utilities for
715 the read quality control and cleaning. A common approach is to use FastQC
716 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/> for read quality control and
717 Trimmomatic (<http://www.usadellab.org/cms/?page=trimmomatic>) for read filtering and
718 trimming. Details about the installation and requirements of these applications on different
719 Operating Systems are available in their reference manuals. The required computational
720 resources depend on the number of sequencing reads, even if a commodity laptop is
721 usually enough to perform all the computation.
- 722 ▪ The BAR-Seq pipeline can be run locally on a Linux computer with Python3 installed and
723 the following pre-requisite packages: numpy, editdistance, network, math, pandas,
724 matplotlib, logomaker (as reported in the github repository
725 <https://bitbucket.org/bereste/bar-seq>). Moreover, the pipeline requires the TagDust2
726 software installed (<http://tagdust.sourceforge.net>). Details about the installation and
727 requirements of these applications on different Operating Systems are available in their
728 reference manuals. The required computational resources depend on the number of
729 sequencing reads, even if a commodity laptop is usually enough to perform all the
730 computation.
- 731 ▪ Alternatively, the BAR-Seq pipeline can be run online using a common laptop with
732 internet access (www.bioinfotiget.com/barseq) and no other specific software installed. A
733 detailed description of the web application usage is present on the website.

734 1.4. REAGENT SETUP

735 **HSPC medium preparation**

736 ! CAUTION – *This reagent preparation must be performed in sterile hood.*

737 For *ex-vivo* culture of CB CD34⁺ HSPCs, serum-free StemSpan™ SFEM medium should be
738 supplemented with 100 IU/mL penicillin, 100 µg/mL streptomycin, 2% (vol/vol) glutamine, 100
739 ng/mL hSCF, 100 ng/mL hFlt3-L, 20 ng/mL hTPO, 20 ng/mL hIL-6, 1 µM SR1, and 50 nM
740 UM171. Medium can be stored at 4°C for maximum 1 week.

741 **Cas9 RNP preparation**

742 ! CAUTION – *This reagent preparation must be performed in sterile hood.*

743 To obtain the required amount of gRNA, mix custom Alt-R® CRISPR-Cas9 crRNA and tracrRNA
744 with a 1:1 ratio, incubate at 95 °C for 5 min and keep cooling at room temperature for 10 min. If
745 single gRNA (purchased by Synthego, or other vendor) is used, there is no need for the annealing
746

748 step. To prepare 25 pmol of RNP complex, add in a new sterile Eppendorf tube 1 μ L DPBS, 0.41 μ L
 749 of Cas9 protein and then gRNA to a predefined gRNA:Cas9 molar ratio (typically ≥ 1.5). Incubate at
 750 room temperature for 15 min to allow complexing. Add 1 μ L of Alt-R® Cas9 Electroporation
 751 Enhancer (0.1 nmol). If single gRNA is used, there is no need to add the electroporation enhancer.

752 **We advise to prepare fresh Cas9 RNP complex.**

753

754 **P3 mix supplementation**

755 **! CAUTION** – *This reagent preparation must be performed in sterile hood.*

756 Add one vial of Supplement 1 Solution (Lonza) to one vial of P3 Primary Cell Nucleofector™
 757 Solution (Lonza). Briefly mix by vortexing. **The supplemented solution can be stored at 4°C for**
 758 **maximum 3 months.**

759

760 **Antibody cocktail for *in vivo* peripheral blood and spleen phenotype**

Target	Fluorochrome	Working Dilution	Amount x 100 μ l (each reaction)
CD45 ⁺	PB	(1:50)	2 μ L
CD19 ⁺	PE	(1:50)	2 μ L
CD13 ⁺	APC	(1:50)	2 μ L
CD3 ⁺	PE-Cy7	(1:50)	2 μ L
CD8 ⁺	APC-H7	(1:50)	2 μ L

761

762 **We advise to prepare fresh antibody cocktail.**

763

764 **Antibody cocktail for *in vivo* bone marrow phenotype**

Target	Fluorochrome	Working Dilution	Amount x 100 μ l (each reaction)
CD45 ⁺	APC-H7	(1:50)	2 μ L
CD34 ⁺	PE-Cy7	(1:50)	2 μ L
CD19 ⁺	PE	(1:50)	2 μ L
CD33 ⁺	PB	(1:50)	2 μ L
CD3 ⁺	APC	(1:50)	2 μ L

765

766 **We advise to prepare fresh antibody cocktail.**

767

768 1.5. EQUIPMENT SETUP

769 **BD FACSAria Fusion**

770 For cell sorting, BD FACSAria Fusion should be equipped with four lasers: blue (488 nm),
771 yellow/green (561 nm), red (640 nm) and violet (405 nm). We advise to use an 85 µm nozzle and set
772 sheath fluid pressure at 45 psi. We recommend a highly pure sorting modality (4-way purity sorting).
773 The drop delay should be determined by BD FACS Accudrop beads prior to sorting.

774

775 **PROCEDURE**

776 **Preparation of the BAR-Seq HDR template library** **TIMING – 4 days**

777 1 Synthesize the complementary strand and amplify the barcoded ssODN using appropriate
778 primers (see **Supplementary Table 3**). Set up an Easy-A High-Fidelity PCR master mix for
779 5 reactions (+1 without barcoded ssODN template as negative control):

780

Component	Amount (each reaction)	No. of reactions	Total amount
Barcoded ssODN	50 pmol	5	250 pmol
10X-Easy-A buffer	5 µL		25 µL
dNTPs (10 mM)	1.2 µL		6 µL
Library Fw (100 µM)	0.5 µL		2.5 µL
Library Rv (100 µM)	0.5 µL		2.5 µL
Easy-A enzyme	0.5 µL		2.5 µL
Molecular-grade H₂O	Up to 50 µL		Up to 250 µL

781

782 Briefly mix and spin, and then load on a thermocycler machine:

783

Step	Number of cycles	Temperature	Duration
1	1	95°C	2 min
2	10	95°C	40 sec
		60°C	30 sec
		72°C	30 sec
3	1	72°C	5 min
4	1	4°C	-

784

785 2 Pool the five reactions and purify them with the MinElute PCR Purification Kit, accordingly
786 to manufacturer's instructions (elution volume = 10 ul).

787 3 Quantify the purified product with NanoDrop 8000.

788 4 Set up digestion reactions of the purified product with restriction enzymes Bsu36I and SphI.
789 Keep 2 µl of the purified undigested product as control.

790

Component	Amount
DNA (from step 2)	8 µL
10X CutSmart buffer	5 µL
Bsu36I	2 µL
SphI	2 µL
Molecular-grade H₂O	23 µL

791

792 5 Incubate at 37°C for 60 min.

793 6 Purify the digestion with the MinElute PCR Purification Kit, accordingly to manufacturer's
794 instructions (elution volume = 11 ul).

795 7 Equilibrate at room temperature the High Sensitivity D1000 Reagents and ScreenTape for 20
796 min.

797 8 Vortex High Sensitivity D1000 Reagents for 30 sec.

798 9 Separately prepare 1:10 and 1:100 dilution of the digested and undigested products; mix by
799 briefly vortexing.

800 10 To verify successful digestion, load on Agilent 4200 TapeStation the dilutions of the digested
801 and undigested products following manufacturer's instructions. In our experience, partial
802 digestion may occur without major impact on the next steps.

803 ? TROUBLESHOOTING

804 11 Use a NanoDrop spectrophotometer to quantify insert template concentration.

805 12 Set up digestion reactions of the non-barcoded plasmid backbone with restriction enzymes
806 Bsu36I and SphI.

807

Component	Amount
Non-barcoded plasmid	40 µg
10X CutSmart buffer	10 µL

Bsu36I	5 μ L
SphI	5 μ L
Molecular-grade H₂O	Up to 100 μ L

808

809 13 Purify the digested plasmid with QIAquick PCR Purification Kit, accordingly to
810 manufacturer's instructions.

811 14 Set up 5' dephosphorylation of the digested plasmid with Antarctic Phosphatase.

812

Component	Amount
Digested plasmid (from step 12)	-
10X Antarctic P. buffer	10 μ L
Antarctic Phosphatase	5 μ L
Molecular-grade H₂O	Up to 100 μ L

813

814 15 Incubate at 37°C for 60 min.

815 16 Prepare 1% agarose gel for plasmid purification upon electrophoresis. Premix the
816 dephosphorylated and digested plasmid from step 13 with the loading dye and load it on the
817 gel. At least 1 μ g of undigested plasmid control and of 1 kb DNA ladder should also be loaded
818 in separate wells to check for plasmid size and effective digestion.

819 17 Read the agarose gel on a GelDoc imager and isolate with a scalpel the portion of agarose gel
820 embedding the DNA band of the dephosphorylated and digested plasmid.

821 *! CAUTION – Avoid direct body exposure to UV light. Always wear UV-light protective*
822 *equipment.*

823 ? TROUBLESHOOTING

824 18 Purify the DNA band with the NucleoSpin® Gel and PCR Clean-up, following
825 manufacturer's instructions (elution volume = 30 μ L). Use a NanoDrop spectrophotometer to
826 quantify plasmid concentration.

827 **PAUSE STEP** – Store at -20°C for long-term storage of the plasmid backbone and the insert
828 template.

829 19 To assess the plasmid:insert molar ratio allowing the higher ligation efficiency, set up three
830 different ligation reactions.

831

Component	Amount
------------------	---------------

Purified plasmid (from step 17)	100 ng
Purified insert (from step 12)	1x, 5x, 10x plasmid moles equivalent
2X T4 ligation buffer	10 μ L
T4 DNA Ligase	1 μ L
Molecular-grade H₂O	Up to 20 μ L

832

833

An additional ligation reaction without the purified insert should be also set up as control.

834

Component	Amount
Purified plasmid (from step 17)	100 ng
2X T4 ligation buffer	10 μ L
T4 DNA Ligase	1 μ L
Molecular-grade H₂O	Up to 20 μ L

835

836

20 Gently mix by pipetting, briefly spin and incubate the reactions at 25°C for at least 60 min.

837

21 Pre-warm at 30°C SOC and LB medium, and 150 mm LB agar plates supplemented with the appropriate antibiotic.

838

839

22 Chill on ice two vials of XL10-Gold Ultracompetent Cells for 5-10 min. Split each vial in two separate pre-chilled Eppendorf tubes (4 tubes total).

840

841

23 Add 2 μ L of β -mercaptoethanol to each tube containing ultracompetent cells and gently swirl the tubes.

842

843

CRITICAL STEP – Avoid vortexing XL10-Gold ultracompetent cells.

844

24 Incubate on ice for 10 min.

845

25 Add 5 μ L of the ligation products to each ultracompetent cells tube and gently swirl.

846

CRITICAL STEP – Avoid vortexing XL10-Gold ultracompetent cells.

847

26 Incubate on ice for 30 min.

848

27 Heat-pulse the tubes at 42°C for 30 sec and then incubate on ice for 2 min.

849

CRITICAL STEP – The duration of the heat-pulse is critical to achieve optimal transformation efficiency. We recommend not to overextend or shorten this time.

850

851

28 Add 450 μ L of prewarmed SOC medium to each tube and incubate them for 60 min at 37°C with shaking at 300 rpm.

852

- 853 29 For each tube containing the bacteria outgrowth from step 27, prepare 1:1, 1:10, 1:50 dilutions
 854 in pre-warmed LB medium (final volume = 300 μ L) and plate them in pre-warmed 150 mm
 855 LB agar plates.
- 856 30 Incubate the plates at 30°C overnight.
- 857 31 Determine/estimate the total number of colonies/plate. This step allows to identify: i) the
 858 plasmid:insert molar ratio that ensures the higher transformation efficiency; ii) the dilution of
 859 bacteria outgrowth avoiding colonies overcrowding in the plate (DF); iii) the maximum
 860 estimated theoretical complexity of the barcoded library when transforming the whole product
 861 of one ligation reaction (“no. of colonies/plate” x “DF” x 4), and therefore the number of
 862 ligation reactions (“M”) required to reach the target library complexity; iv) the number of
 863 XL10-Gold vials (“V”) and 150 mm LB agar plates (“P”) needed for the library production.
 864 *CRITICAL STEP – We advise to count the number of colonies in a subarea of the plate and
 865 then multiply this number for the area:subarea ratio. The number of colonies may be
 866 uncountable at 1:1 and 1:10 dilutions. Furthermore, the estimated number of colonies in the
 867 control condition should be at least 10⁴-fold lower than in the other plates to minimize the
 868 chance of having clones carrying the non-barcoded template.*
- 869 ? TROUBLESHOOTING
- 870 32 Having identified the optimal plasmid:insert molar ratio for ligation, set up “M” ligation
 871 reactions by scaling up calculations from step 18.
 872

Component	Amount
Purified plasmid (from step 17)	100 ng x M
Purified insert (from step 12)	Determined in step 30 x M
2X T4 ligation buffer	10 μ L x M
T4 DNA Ligase	1 μ L x M
Molecular-grade H₂O	Up to 20 μ L x M

- 873
- 874 33 Gently mix by pipetting, briefly spin and incubate the reactions at 25°C for at least 60 min.
- 875 34 Pre-warm at 30°C SOC and LB medium and 150 mm LB agar plates supplemented with the
 876 appropriate antibiotic.
- 877 35 Chill on ice a total number of “V” vials (as determined in step 30) of XL10-Gold
 878 ultracompetent cells for 5-10 min.
- 879 36 Add 4 μ L of β -mercaptoethanol to each tube containing ultracompetent cells and gently swirl
 880 the tubes.

881 CRITICAL STEP – *Avoid vortexing XL10-Gold ultracompetent cells.*

882 37 Incubate on ice for 10 min.

883 38 Add 10 µL of the ligation products to each ultracompetent cells tube and gently swirl.

884 CRITICAL STEP – *Avoid vortexing XL10-Gold ultracompetent cells.*

885 39 Incubate on ice for 30 min.

886 40 Heat-pulse the tubes at 42°C for 30 sec and then incubate on ice for 2 min.

887 CRITICAL STEP – *The duration of the heat-pulse is critical to achieve optimal*

888 *transformation efficiency. We recommend not to overextend or shorten this time.*

889 41 Add 900 µL of pre-warmed SOC medium to each tube and incubate them for 60 min at 37°C

890 with shaking at 300 rpm.

891 42 Pool the bacteria outgrowths from step 42 in 15- or 50-mL Falcon tubes. Add pre-warmed LB

892 medium to reach the predetermined “DF” dilution and plate in “P” 150 mm LB agar plates

893 (as determined in step 30).

894 43 Incubate the plates at 30°C overnight and verify that the number of colonies is in agreement

895 with the calculations from step 31.

896 44 Add 3 mL of LB medium (supplemented with the appropriate antibiotic) on the top of each

897 LB agar plate. Scrape bacteria colonies by using bacteria spreaders. Collect, pool and

898 thoroughly mix by pipetting the LB medium derived from each plate.

899 45 Inoculate 20-50 mL of the scraped product in 500 mL of LB medium and incubate at 30°C

900 for additional 6 hours.

901 46 Perform plasmid extraction and purification from the bacteria outgrowth with the NucleoBond

902 Xtra Maxi EF following manufacturer’s instructions. Use a NanoDrop spectrophotometer to

903 quantify plasmid concentration.

904 47 (Optional) Set up enzymatic digestion of 1 µg of the BAR-Seq plasmid library to check for

905 plasmid integrity by gel electrophoresis. This step is strongly recommended in case the

906 plasmid contains repeated sequences, such as AAV ITRs.

907 PAUSE STEP – *Store at -20°C for long-term storage.*

908 CRITICAL STEP – *Assess the diversity of the BAR-Seq plasmid library by deep-sequencing*

909 *the BAR region (Box 1). Proceed to the next steps only if the library complexity and diversity*

910 *are sufficient to univocally tag cell clones in the target population of interest (as discussed in*

911 *the “Experimental design”).*

912 ? TROUBLESHOOTING

913 48 (Optional) The BAR-Seq plasmid library is ready to use in gene editing experiments.
914 Alternatively, the BAR-Seq plasmid library may serve as transfer plasmid for BAR-Seq viral
915 library production.

916 ? TROUBLESHOOTING

917 CRITICAL STEP – *Assess the diversity of the BAR-Seq viral library before moving on to gene*
918 *editing experiments by following steps provided in **Box 2**.*

919

920 **Thawing of CB CD34⁺ HSPCs** TIMING – day ‘0’ of the editing procedure– **30 min**

921 ! CAUTION – *Cell culture and gene editing procedure must be performed in sterile hood.*

922 CRITICAL STEP – *CB CD34⁺ HSPCs are purchased frozen from Lonza and contain at least*
923 *1x10⁶ total cells. HSPCs must be conserved in liquid nitrogen.*

924 49 Determine the number of culture-initiating CB HSPCs required for the experiment.

925 CRITICAL STEP – *Transplantation of higher number of culture-initiating HSPCs in sub-*
926 *lethally irradiated NSG mice results in the saturation of the hematopoietic niche. Therefore,*
927 *the number of transplanted culture-initiating HSPCs is critical to potentially uncover*
928 *differences in the clonality or repopulation capacity of edited cells. In our experience, below*
929 *1.5 x 10⁵ and above 3 x 10⁵ culture-initiating CB HSPCs/mouse are limiting or saturating*
930 *ranges for cell doses, respectively.*

931 CRITICAL STEP – *If more than one vial is required, we strongly suggest to pool cells from*
932 *different donors to reduce inherent variability.*

933 50 Pre-warm the supplemented StemSpan™ medium (see Reagent setup) at 37°C.

934 51 Thaw CB CD34⁺ cells by immersing the vial in water bath at 37°C water for 5 min.

935 52 Transfer the cells solution in a 50-mL sterile Falcon tube, add “drop-by-drop” 10 volumes of
936 DMEM medium and pellet them using the centrifuge 5810R (1100 rpm, room temperature,
937 10 min).

938 53 Carefully aspirate and discard the supernatant. Quickly and gently resuspend cell pellet with
939 the pre-warmed StemSpan™ medium. Seed cells at the concentration 5 x 10⁵ cells/mL.

940 CRITICAL STEP – *This cell concentration favors cell cycling during pre-stimulation*
941 *while promoting cell maintenance.*

942 54 Add dmPGE₂ to the culture medium (final concentration = 10 μM) and mix well by pipetting.

943 CRITICAL STEP – *dmPGE₂ protects CB HSPCs from thawing toxicity and preserves their*
944 *stemness properties¹⁸. dmPGE₂ should not be further supplemented in the medium after the*
945 *editing procedure.*

946 55 Incubate cells for three days at 37°C in a 5% CO₂ and 20% O₂ humidified atmosphere.

947 CRITICAL STEP – *In our experience, three-days expansion of HSPCs before gene editing*
948 *procedure allows to maximize HDR efficiency in the long-term repopulating HSPC*
949 *compartment* (¹⁸ and unpublished data).

950

951 **Gene editing procedure of cultured HSPCs** TIMING – day ‘+3’ of the editing procedure – **1-2**
952 **hours**

953 56 Pre-warm the supplemented StemSpan™ medium at 37°C (see Reagent setup).
954 57 Count the number of viable cultured HSPCs, collect 1-5x10⁵ cells in a 1.5-mL sterile
955 Eppendorf tube, add 10 volumes of DPBS and pellet them using the centrifuge 5430 (2250
956 rpm, room temperature, 10 min).

957 58 Carefully aspirate and discard the supernatant. Resuspend cell pellet with P3 Primary solution
958 mix (see Reagent setup) and add the RNP complex to reach a final volume of 20 µL/sample.

959 CRITICAL STEP – *The electroporation mixture may be supplemented with mRNA(s) to*
960 *overexpress proteins of interest, as previously described for editing enhancers*^{9,42}. *For optimal*
961 *electroporation efficiency and lower cytotoxicity, the volume of the P3 primary solution mix*
962 *should not be lower than 70% of the total electroporation volume. The final electroporation*
963 *volume may be increased up to 25 µL/sample, if required. Be aware that increasing the*
964 *electroporation volume above 25 µL/sample may cause electroporation failure.*

965 59 Transfer the cell solution to 4D-Nucleofector™ strip for each condition/mouse and proceed
966 immediately to electroporation using the pre-recorded manufacturer’s human CD34⁺ **EO-100**
967 program.

968 60 Wait 1 minute and then add 180 µL of pre-warmed StemSpan™ medium. Transfer cells to an
969 adequate well-plate to reach the final concentration of 1 x 10⁶ cells/mL.

970 CRITICAL STEP – *Cells belonging to the same experimental condition can be pooled.*

971 61 Incubate cells for **15 min** at 37°C in a 5% CO₂ and 20% O₂ humidified atmosphere.

972 62 Transduce electroporated cells with the BAR-Seq AAV6 library at multiplicity of infection
973 (MOI) = 20.000 vg/cell and gently mix by pipetting.

974 CRITICAL STEP – *Keep the virus stock on ice. Do not thaw more than 3 times the same AAV*
975 *aliquot to assure virus stability and reproducibility in results.*

976 63 Incubate cells for **24 hours** at 37°C in a 5% CO₂ and 20% O₂ humidified atmosphere.

977 CRITICAL STEP – *In our experience, 24 hours is the minimum recovery time to avoid loss of*
978 *cell engraftment after transplantation in NSG mice.*

979

980 **Transplantation of edited HSPCs in immunodeficient NSG mice** **TIMING** – day ‘+4’ of the
981 **editing procedure – 2 hours**

- 982 64 Irradiate NSG female mice at 190 rad at least 4 hours before cells transplantation.
- 983 *CRITICAL STEP – We advise considering at least 5 mice per experimental group and ideally*
984 *the experiment should be repeated twice to allow reliable statistical analysis. Mice should be*
985 *randomly distributed across the experimental groups.*
- 986 65 Count the number of viable edited HSPCs, collect all cells in a new 15-mL sterile Falcon tube,
987 add 10 volumes of DPBS and pellet them using the centrifuge 5810R (1100 rpm, room
988 temperature, 10 min).
- 989 66 Carefully aspirate and discard the supernatant. Resuspend cell pellet with DPBS to a final
990 volume of 200 µL x no. mice to be transplanted/group + 50 µL excess.
- 991 67 Aliquot 200 µL in individual sterile 1.5 mL Eppendorf tubes (one for each mouse) and keep
992 them on ice until transplantation.
- 993 68 Immediately proceed to transplant irradiated NSG mice. Perform intravenous tail-vein
994 injection with the previously prepared 200 µL of DPBS containing edited HSPCs by using a
995 sterile 0.5 mL insulin syringe with a 29-gauge x 12,7 mm needle.
- 996 *CRITICAL STEP – Do not keep HSPCs on ice for too long to avoid cytotoxicity. Mouse tail*
997 *may be pre-warmed with red-light lamp to ease injection. In case of potentially uncomplete*
998 *or failed injection, the mouse should be univocally marked and must be excluded from the*
999 *experiment in case engraftment failure is confirmed by flow cytometry analyses.*
- 1000 *! CAUTION – Carefully handle syringes to avoid punctures.*
- 1001 69 Collect the remaining 50 µL of DPBS with edited HSPCs and add supplemented StemSpan™
1002 medium to reach a final concentration of 5x10⁵ cells/mL. If the final volume is < 500 µL,
1003 pellet cells using the centrifuge 5430 (2250 rpm, room temperature, 10 min) before adding
1004 the medium and carefully remove the supernatant.
- 1005 70 Culture HSPCs at 37°C in a 5% CO₂ and 20% O₂ humidified atmosphere for additional seven
1006 days to proceed with *in vitro* clonal analysis.
- 1007 *CRITICAL STEP – In vitro clonal analysis can be performed even after seven days of culture.*
1008 *We recommend caution when shortening this time of culture since barcoded template dilution*
1009 *may be uncomplete and thus PCR jumping may occur between on-target integrated barcodes*
1010 *and episomal barcoded AAV. In vitro clonal analysis may also be performed on sorted cell*
1011 *subpopulations.*

1012 71 (Optional) Further characterization of edited HSPCs *in vitro* may be relevant for the
1013 interpretation of clonality data, such as *in vitro* clonogenic capacity (**Box 3**), cell phenotype
1014 (**Box 4**), HDR/NHEJ editing efficiency (**Boxes 5 and 6**).

1015 ? TROUBLESHOOTING

1016

1017 **Sample preparation for BAR-Seq analysis on cultured HSPCs** TIMING – day ‘+10’ of the editing
1018 **procedure – 2 hours**

1019 72 Collect >200,000 cultured HSPCs for each experimental condition, add 10 volumes of DPBS
1020 and pellet them using the centrifuge 5430 (2250 rpm, room temperature, 10 min).

1021 73 Aspirate and discard the supernatant.

1022 PAUSE STEP – *The cell pellet may be frozen at -80°C for long-term storage.*

1023 74 Extract gDNA using the QIAamp DNA Micro Kit, accordingly to manufacturer’s instructions.

1024 Use a NanoDrop spectrophotometer to quantify DNA concentration.

1025 PAUSE STEP – *gDNA samples are now ready for BAR-Seq clonal analysis following steps*
1026 *from 104 to the end. gDNA can be frozen at +4 or -20°C for short- or long-term storage,*
1027 *respectively.*

1028

1029 **Phenotypic analysis of peripheral blood samples from transplanted NSG mice** TIMING – 3
1030 **hours / time point**

1031 75 Every 3 weeks after the time of transplant, perform blood collection from transplanted NSG
1032 mice. For each mouse, prepare one 1.5-mL sterile Eppendorf tube with 20 µL of EDTA.

1033 *CRITICAL STEP – The size of the human cell graft may be low (< 1%) until 6 weeks after*
1034 *transplant if limiting doses of culture-initiating HSPCs were transplanted. Too low number*
1035 *of circulating human cells may decrease the reliability of further clonal analysis.*

1036 76 For each mouse, collect 100-200 µL of peripheral blood from tail vein sampling.

1037 77 Homogenized well by repeatedly flicking the Eppendorf tubes.

1038 78 Transfer 50 µL of blood in an individual new FACS tube for each mouse, add the Fc block
1039 anti-mouse (0.5 µL/sample) and anti-human (1 µL/sample), and incubate for 10 min at room
1040 temperature.

1041 79 Add the dedicated anti-human antibodies for cell lineages characterization (see Reagent setup)
1042 and incubate for 15 min at 4°C.

1043 80 Add 50 µL of FBS and vortex well before to perform automated red blood cell lysis with the
1044 TQ-Prep™ Workstation following manufacturer’s procedure.

1045 81 Wash the cells by filling the tube with DPBS + 2% FBS and pellet cells by using the centrifuge
1046 5810R (1100 rpm, room temperature, 10 min). Discard the supernatant.

1047 *PAUSE STEP – The stained sample may be kept at 4°C for up to 1-2 hours.*

1048 82 Add 1 µL of 7-AAD to each sample for live/dead staining and briefly mix by vortexing.

1049 83 Incubate for 10 min and then perform flow cytometry analysis with BD FACS Canto II.

1050 ? TROUBLESHOOTING

1051

1052 **Sample preparation for BAR-Seq analysis on peripheral blood of transplanted NSG mice**

1053 **TIMING – 2 hours / time point**

1054 84 Add 200 µL of ACK lysing buffer to the remaining 100-150 µL of blood sample and
1055 thoroughly vortex.

1056 85 Incubate for 5 min at room temperature.

1057 86 Wash with 500 µL of DPBS + 2% FBS and centrifuge (1100 rpm, room temperature, 10 min).
1058 Aspirate and discard the supernatant.

1059 *PAUSE STEP – The cell pellet may be frozen at -80°C for long-term storage.*

1060 87 Extract gDNA using the QIAamp DNA Micro Kit, accordingly to manufacturer's instructions.
1061 Use a NanoDrop spectrophotometer to quantify DNA concentration.

1062 *PAUSE STEP – gDNA samples are now ready for BAR-Seq clonal analysis following steps*
1063 *from 104 to the end. gDNA can be frozen at +4 or -20°C for short- or long-term storage,*
1064 *respectively.*

1065

1066 **Sample preparation for cell sorting from hematopoietic organs of transplanted NSG mice**

1067 **TIMING – 3 hours / 10 animals**

1068 88 After 18-20 weeks after transplant, NSG mice may be euthanized accordingly to the approved
1069 institution protocol.

1070 89 Collect cells from spleen by crushing and from posterior legs' bone marrow by flushing.

1071 **Spleen:**

1072 *CRITICAL STEP – In order to minimize clumps formation, we strongly recommend working*
1073 *on ice and using cold reagents when processing the spleen.*

1074 90 Crush the spleen and filter cells using the 40 µm cell strainer with cold MACS Buffer.

1075 91 Centrifuge the homogenate (1300 rpm, 4 °C, 10 min) and then discard the supernatant.

1076 92 Add 1 mL of cold ACK lysing buffer to the cell pellet, thoroughly vortex and incubate for 5
1077 min at room temperature.

1078 93 Wash with cold MACS buffer up to filling the tube, centrifuge (1300 rpm, 4°C, 10 min) and
1079 then discard the supernatant.

1080 94 Resuspend the cell pellet with 5 mL of cold MACS Buffer and then filter cell suspension
1081 with the 40 µM cell strainer. Centrifuge (1300 rpm, 4°C, 10 min) and then discard the
1082 supernatant. Proceed to step 97.

1083 Bone marrow:

1084 95 Flush bone marrow from posterior legs using cold MACS buffer and a 10 mL syringe with 1
1085 mL needle.

1086 96 Filter the cells using a 40 µM cell strainer, centrifuge (1300 rpm, 4°C, 10 min) and then
1087 discard the supernatant. Proceed to step 97.

1088

1089 **Staining, cell sorting from hematopoietic organs of transplanted NSG mice and sample**
1090 **preparation for BAR-Seq clonal analysis** *TIMING – 5 hours / 10 animals*

1091 97 Resuspend the cell pellet with 200 µL of cold MACS Buffer, add the Fc block anti-mouse (1
1092 µL/sample) and anti-human (2 µL/sample) and incubate for 10 min at room temperature.

1093 98 Add the dedicated anti-human antibodies for cell lineages characterization (see Reagent setup)
1094 and incubate for 15 min at 4°C.

1095 99 Wash the cells by filling the tube with DPBS + 2% FBS and pellet cells by using the centrifuge
1096 5810R (1100 rpm, room temperature, 10 min). Discard the supernatant.

1097 *PAUSE STEP – The stained sample may be kept at 4°C for up to 1-2 hours.*

1098 100 Resuspend the cells in the desired volume for cell sorting. Add 2 µL of 7-AAD to each sample
1099 for live/dead staining and briefly mix by vortexing.

1100 *CRITICAL STEP – To facilitate high-speed sorting and to prevent clogging of the nozzle,*
1101 *filter the samples through 35 µm filter immediately prior to sorting and dilute them such that*
1102 *at a flow rate of 2.0 an event rate of 5,000/10,000 events/second is not exceeded.*

1103 101 Sort cell subpopulations of interest with BD FACSAria Fusion and collect samples in 1.5
1104 mL Eppendorf tubes containing 500 µL of DPBS.

1105 *CRITICAL STEP – We recommend using unstained and single-stained controls to set up*
1106 *compensation. Rainbow beads (SPHERO™ Rainbow Calibration Particles) should be*
1107 *included to standardize the experiments and have to be run before each acquisition.*

1108 102 Centrifuge the sorted cells (2250 rpm, room temperature, 10 min). Aspirate and discard the
1109 supernatant.

1110 *CRITICAL STEP – We recommend not to perform this step if the number of sorted cells is*
1111 *below 1,000 events and instead directly freeze the cells or proceed with gDNA extraction.*

1112 PAUSE STEP – *The cell pellet can be frozen at -80°C for long-term storage.*
 1113 103 Extract gDNA using the QIAamp DNA Micro Kit, accordingly to manufacturer’s instructions.
 1114 Use a NanoDrop spectrophotometer to quantify DNA concentration.
 1115 PAUSE STEP – *gDNA samples are now ready for BAR-Seq clonal analysis following steps*
 1116 *from 104 to the end. gDNA may be frozen at +4 or -20°C for short- or long-term storage,*
 1117 *respectively.*

1118
 1119 **BAR-Seq library preparation TIMING – 4 hours / 49 samples**

1120 CRITICAL STEP – *We advise performing steps 104-105 using LoBind disposable material*
 1121 *and working in dedicated vertical laminar-flow hood, unless otherwise specified. We also*
 1122 *recommend to carefully clean pipettes and the working area with DNA decontamination*
 1123 *reagents before moving to the next steps.*

1124 104 Set up the first PCR reaction for samples from step 74, 87 and/or 103 (up to a maximum of
 1125 49 samples + 1 “no template control”) on ice in a LoBind 96-well plate.

1126

Component	Amount (each reaction)
gDNA (from step 48, 74, 87 or 103)	100 ng (or up to 10-15 µL)
5X GoTaq® reaction buffer	5 µL
MgCl₂ (25 mM)	4 µL
dNTPs (10 mM)	1.2 µL
Primer PCR1_Fw (100 µM)	0.5 µL
Primer PCR1_Rv (100 µM)	0.5 µL
GoTaq G2 DNA Polymerase (5U/µl)	0.5 µL
Molecular-grade H₂O	Up to 50 µL

1127

1128 Seal the plate with a pierceable foil, briefly mix and spin. Load the PCR reactions on a
 1129 thermocycler machine using the following PCR program.

1130

Step	Number of cycles	Temperature	Duration
1	1	95°C	5 min
2	Up to 15-20	95°C	30 sec

		T _m – 5°C	30 sec
		72°C	depending on amplicon length
3	1	72°C	5 min
4	1	4°C	-

1131

1132

1133

1134

CRITICAL STEP – *Pfu DNA Polymerase (Promega)* can be also used to further increase fidelity during amplification. In this case, the PCR program should be modified accordingly to manufacturer’s instructions.

1135

1136

CRITICAL STEP – *Plasmid DNA from step 47* can be used instead of *gDNA* to characterize library *diversity*.

1137

105Set up the second PCR reaction on ice in a new LoBind 96-well plate.

1138

Component	Amount (each reaction)
5X GoTaq® reaction buffer	5 µL
MgCl₂ (25 mM)	4 µL
dNTPs (10 mM)	1.2 µL
GoTaq G2 DNA Polymerase	0.5 µL
Molecular-grade H₂O	Up to 44 µL

1139

1140

1141

1142

1143

1144

1145

In a vertical laminar-flow hood, carefully add 0.5 µL of primer “PCR2_Fw#” and 0.5 µL of primer “PCR2_Rv#” for each sample. In a dedicated bench, carefully add 5 µL of PCR product from step 104 by piercing the foil with the tips loaded on a multichannel pipette. Seal the plate with a new pierceable foil, briefly mix and spin. Load the PCR reactions on a thermocycler machine using the following PCR program.

Step	Number of cycles	Temperature	Duration
1	1	95°C	5 min
2	Up to 15-20	95°C	30 sec
		T _m – 5°C	30 sec
		72°C	depending on amplicon length

3	1	72°C	5 min
4	1	4°C	-

1146

1147

CRITICAL STEP – *Pfu DNA Polymerase (Promega)* can be also used to further increase fidelity during amplification. In this case, the PCR program should be modified accordingly to manufacturer’s instructions.

1149

1150

! CAUTION – Addition of primers and PCR products should be performed very carefully to avoid cross-contaminations among samples.

1151

1152

106 Equilibrate at room temperature the High Sensitivity D1000 Reagents and ScreenTape for 20 min.

1153

1154

107Vortex High Sensitivity D1000 Reagents for 30 sec.

1155

108Separately prepare 1:10 dilutions of 1 µL PCR products from the second amplification round.

1156

Mix by briefly vortexing.

1157

109To verify for successful amplification, load on Agilent 4200 TapeStation the diluted PCR products following manufacturer’s instructions.

1158

1159

PAUSE STEP – *PCR products can be frozen at -20°C before purification.*

1160

? TROUBLESHOOTING

1161

110Purify the PCR product using AMPure XP beads following manufacturer’s instructions (final volume = 17.5 µL).

1162

1163

111Quantify amplicon concentration for each sample by Agilent 4200 TapeStation following steps 106-109 and manufacturer’s instructions.

1164

1165

PAUSE STEP – *Purified amplicons can be frozen at -20°C for long-term storage.*

1166

1167

Next-generation sequencing of the BAR-Seq amplicons TIMING – 1 day / sequencing run

1168

112Submit samples to your sequencing facility. We tested the protocol on both Illumina NextSeq500 and MiSeq platforms, following the manufacturer's instructions. **Single-end sequencing is sufficient.**

1169

1170

1171

CRITICAL STEP – *We recommend adding PhiX at 30-40% to ensure proper reading of amplicons.*

1172

1173

1174

BAR-Seq bioinformatic analyses TIMING – 8 hours / 49 samples

1175

Local execution

1176 113(Optional) Pre-process the input reads (usually in FASTQ format) to check their quality and
1177 perform a filter/trim to remove low quality portions or sequencing adapters (i.e. using FastQC
1178 and Trimmonatic), if required.

1179 114Extract the barcode sequences from the input reads, based on the amplicon structure, using
1180 TagDust2 (**Figure 3**).

1181 CRITICAL STEP – *The percentage of reads from which a valid BAR is extracted should be*
1182 *above 80%.*

1183 ? TROUBLESHOOTING

1184 115Perform the filtering of extracted reads based on their length and structure, and then correct
1185 the erroneous ones by employing the graph-based procedure which identifies and merges the
1186 ego-(sub)networks used to represent the similarity among barcode sequences.

1187 116Select the threshold for the minimum BAR abundance (e.g. 3) and discard those having lower
1188 counts. The remaining sequences are the set of valid BARs.

1189 ? TROUBLESHOOTING

1190 117Rank the BARs from the most to the least abundant and identify the dominant and rare
1191 (sub)populations by applying a saturation-based approach based on the selected threshold
1192 (e.g. 90%).

1193 118(Optional) If more samples are analyzed, compute the BAR sharing among them, by
1194 considering the overall set of valid sequences and keeping track of their abundance in each
1195 sample. The same can be done by considering only the dominant BARs.

1196 119(Optional) Compute the sample diversity and the level of richness for each sample to check if
1197 the set of BARs is informative enough. Optimal experiments should achieve high richness
1198 values ($R > 0.7$), while low richness levels ($R < 0.3$) could indicate poor sequencing depth. In
1199 this case, amplicon preparation and/or sequencing must be re-performed by following the
1200 suggestions reported in the **Troubleshooting** guide.

1201

1202 Online execution (alternative to steps 113 – 119)

1203 120Run the BAR-Seq pipeline online by visiting the web-application page
1204 <http://www.bioinfotiget.it/barseq> (**Figure 4**).

1205 121Upload your set of pre-processed FASTQ files (one for each sample) containing the input
1206 sequences.

1207 CRITICAL STEP – *We set a limit of 500MB for the total size of the uploaded samples to*
1208 *avoid overloading the server. Anyway, upon specific request, this size limit can be increased.*

1209 122Specify the known sequences flanking the BAR within the amplicon (upstream and
1210 downstream).

1211 123Select filter thresholds for “Min. Barcode Count” and “Saturation Threshold (%)”.

1212 124(Optional) In the “Advanced Options” select the “Structural Filter” by choosing among “No
1213 Filter”, “Filter Nucleotide with Freq. < 1%”, and “Fixed Structure” which requires an IUPAC
1214 sequence with the structure. The “Graph Edit Distance” can also be customized.

1215 125Press the “Run” button to perform the computation remotely. BAR-Seq results are shown and
1216 can be downloaded.

1217 CRITICAL STEP – *We advise to pay attention when specifying the two sequences flanking*
1218 *the BAR for its extraction. The percentage of reads from which a valid BAR is extracted should*
1219 *be above 80%.*

1220 ? TROUBLESHOOTING

1221 126(Optional) To check if the set of BARs is informative, compute the sample diversity and the
1222 level of richness for each sample by clicking on the “Check Diversity/Richness” button in the
1223 “Results” page. Select the desired confidence level and press “Run”. Optimal experiments
1224 should achieve high richness values ($R > 0.7$), while low richness levels ($R < 0.3$) could indicate
1225 poor sequencing depth. If the set of BARs is not informative enough, amplicon preparation or
1226 sequencing must be re-performed by following the suggestions reported in the
1227 **Troubleshooting** guide.

1228 CRITICAL STEP – *Alternatively, the downloaded text file containing the set of valid BARs*
1229 *(from step 125) can be manually uploaded by clicking on the “Check Diversity/Richness” tab*
1230 *in the homepage.*

1231 CRITICAL STEP – *When analyzing the original plasmid/viral library, the table in the “Check*
1232 *Diversity/Richness” result page provides an estimation of the number of uniquely labeled*
1233 *cells that can be tracked with a certain confidence level by using the given library.*

1234 ? TROUBLESHOOTING

1235

1236 TIMING

1237 Step 1-48, preparation of the barcoded HDR template: 4-5 days.

1238 Step 49-55, thawing of CB CD34⁺ HSPCs: 30 min hands-on, 3 days of culture.

1239 Step 56-63, gene editing procedure of cultured HSPCs: 1-2 hours hands-on, 1 day of culture.

1240 Step 64-71, transplantation of edited HSPCs in immunodeficient NSG mice: 2 hours hands-on.

1241 Step 72-74, sample preparation for BAR-Seq analysis on cultured HSPCs: 2 hours hands on.

1242 Step 75-83, phenotypic analysis of peripheral blood samples from transplanted NSG mice: 3 hours
 1243 hands-on / time point.
 1244 Step 84-87, sample preparation for BAR-Seq analysis on peripheral blood of transplanted NSG
 1245 mice: 2 hours hands-on / time point.
 1246 Step 88-96, sample preparation for cell sorting from hematopoietic organs of transplanted NSG
 1247 mice: 3 hours hands-on / 10 animals.
 1248 Step 97-103, staining, cell sorting from hematopoietic organs of transplanted NSG mice and sample
 1249 preparation for BAR-Seq clonal analysis: 5 hours hands-on / 10 animals.
 1250 Step 104-111, BAR-Seq library preparation: 4 hours hands-on / 49 samples.
 1251 Step 112, Next-generation sequencing of the BAR-Seq amplicons: 1 day / sequencing run
 1252 Step 113-119 or 120-126, BAR-Seq bioinformatics analysis: 8 hours / 49 samples.

1253

1254 **TROUBLESHOOTING**

Step	Problem	Possible reasons	Possible solutions
10	Absence of the peaks corresponding to successful digestion	Inefficient ssODN amplification	Decrease the amount of ssODN/reaction
			Repeat amplification using different polymerases (e.g. Pfu)
		Inefficient restriction enzyme activity (<40% digested product)	Increase the restriction enzyme units and/or the incubation time
			Use new stocks of restriction enzymes
17	Absence of the expected digestion pattern	Inefficient restriction enzyme activity	Increase the restriction enzyme units
			Use new stocks of restriction enzymes
		Ethanol traces in the plasmid prep	Precipitate the plasmid prep, wash, resuspend the pellet and perform again digestion
31	Too low number of colonies/plate	Poor transformation efficiency	Improve transformation efficiency by testing other ligation/transformation conditions
			Performing again backbone/insert digestions
	Too high number of colonies/plate	Highly efficient transformation	Use >100 plates/vial of ultracompetent cells in step 42

	High number of colonies in the "backbone only" control plates	Inefficient/incomplete digestion of the plasmid backbone	Repeat plasmid digestion increasing the units of restriction enzymes or decreasing the starting amount of plasmid
47/48 (related to Box1 and Box2)	Low complexity of the barcoded library	Inefficient ligation/transformation	Increase the number of ultracompetent cells vials used for transformation and/or the number of ligation reactions
			See troubleshooting for step 31
71	Low HDR editing efficiency	Inefficient gRNA cleavage activity	Evaluate cutting efficiency by T7 endonuclease assay, increase the RNP dose or change the Cas9:gRNA ratio
		Low permissiveness of the locus to HDR	Include Ad5-E4orf6/7 (+/- GSE56) mRNA during electroporation (note: GSE56 enhances clonality of edited HSPCs)
83	Low human cell engraftment	High toxicity of the editing procedure	Optimize editing conditions by decreasing AAV or RNP doses
			Include GSE56 mRNA during electroporation (note: GSE56 enhances clonality of edited HSPCs)
		HSPC donor variability	Pool HSPCs from different donors
109	Absent amplicon peak or low amplicon concentration	Low yield of gDNA (<1 ng/uL)	Start with >1,000 cells
		Low HDR editing efficiency (<1%) and or low human cell engraftment (<1%)	See troubleshooting for step 71/83
114 /116 /125	Low percentage of barcode retrieved	Possible errors in defining the read structure	Check barcode flanking sequences provided to TagDust in the BAR-Seq software utility
119 /126		Low number of reads to capture the barcode	Perform again amplicon preparation increasing the amount of DNA

	Poor richness for some samples	complexity of the sample	Re-sequence samples with poor richness increasing depth (i.e. decreasing the number of samples multiplexed in the run
--	--------------------------------	--------------------------	---

1255

1256 ANTICIPATED RESULTS

1257 BAR-Seq pipeline is designed to perform clonal tracking analyses of edited cells both *in vitro*
 1258 and *in vivo*, without any limitation due to the locus, donor template or nuclease platform. We easily
 1259 obtain BAR-Seq plasmid libraries with $3-8 \times 10^5$ unique BARs and we observe **only minimal** skewing
 1260 in BAR abundance from plasmid to **viral library**⁹. **As discussed above, the required library complexity**
 1261 **and diversity strictly depend on the expected complexity of the cell population of interest and the**
 1262 **desired number of traceable cells. The BAR-Seq web application provides a function which estimates**
 1263 **whether the sequenced plasmid/viral library is suitable for clonal tracking of a desired number of**
 1264 **cells. Software outputs for good (highly diverse) and bad (poorly diverse) libraries are shown in**
 1265 **Figure 5a.**

1266 The experimental procedure described in this Protocol allows efficient BAR extraction from
 1267 gDNA of edited cells. An example of the amplicon library profile is shown in **Figure 5b.**

1268 When applied to clonal tracking of edited HSPCs, BAR-Seq uncovered the multilineage and
 1269 self-renewing capacity of engrafting HDR-edited HSPCs in human hematochimeric mice with the
 1270 majority of clones shared among cell lineages long-term after transplant. Moreover, the human HDR-
 1271 edited cell graft was composed by few highly abundant clones. Higher complexity of the clonal
 1272 repertoire can be achieved by dampening the editing-induced p53-dependent DNA-damage response
 1273 and enhancing editing efficiency⁹.

1274

1275 DATA AVAILABILITY

1276 The BAR-Seq software with some example datasets are provided as a zip file in the
 1277 **Supplementary Materials.** Moreover, the datasets available in Gene Expression Omnibus with the
 1278 access code GSE144340 have been analyzed using the BAR-Seq pipeline as described in⁹, including
 1279 those presented as examples in **Figure 4.**

1280

1281 CODE AVAILABILITY

1282 The scripts for BAR-Seq analysis are freely available at <https://bitbucket.org/bereste/bar-seq>.
 1283 The BAR-Seq webtool is freely available at <http://www.bioinfotiget.it/barseq>.

1284

1285 **ETHICAL STATEMENT**

1286 All experiments and procedures involving animals were performed with the approval of the
1287 Animal Care and Use Committee of the San Raffaele Hospital (IACUC no. 749) and authorized by
1288 the Italian Ministry of Health and local authorities accordingly to Italian law.

1289 The use of human HSPCs was approved by the Ospedale San Raffaele Scientific Institute
1290 Bioethical Committee (TIGET-HPCT protocol).

1291

1292 **REFERENCES**

- 1293 1. Naldini, L. Gene therapy returns to centre stage. *Nature* (2015). doi:10.1038/nature15818
- 1294 2. Bramlett, C. *et al.* Clonal tracking using embedded viral barcoding and high-throughput
1295 sequencing. *Nat. Protoc.* (2020). doi:10.1038/s41596-019-0290-z
- 1296 3. Cavazzana-Calvo, M. *et al.* Gene therapy of human severe combined immunodeficiency
1297 (SCID)-X1 disease. *Science* (80-.). **288**, 669–672 (2000).
- 1298 4. Biffi, A. *et al.* Lentiviral hematopoietic stem cell gene therapy benefits metachromatic
1299 leukodystrophy. *Science* (80-.). **341**, (2013).
- 1300 5. Aiuti, A. *et al.* Lentiviral hematopoietic stem cell gene therapy in patients with wiskott-
1301 aldrich syndrome. *Science* (80-.). **341**, (2013).
- 1302 6. Scala, S. *et al.* Dynamics of genetically engineered hematopoietic stem and progenitor cells
1303 after autologous transplantation in humans. *Nat. Med.* (2018). doi:10.1038/s41591-018-0195-
1304 3
- 1305 7. Wu, C. *et al.* Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage
1306 origin for natural killer cells. *Cell Stem Cell* (2014). doi:10.1016/j.stem.2014.01.020
- 1307 8. Doudna, J. A. The promise and challenge of therapeutic genome editing. *Nature* **578**, 229–
1308 236 (2020).
- 1309 9. Ferrari, S. *et al.* Efficient gene editing of human long-term hematopoietic stem cells
1310 validated by clonal tracking. *Nat. Biotechnol.* (2020). doi:10.1038/s41587-020-0551-y
- 1311 10. Keschull, J. M. & Zador, A. M. Cellular barcoding: lineage tracing, screening and beyond.
1312 *Nature Methods* (2018). doi:10.1038/s41592-018-0185-x
- 1313 11. Lu, R., Neff, N. F., Quake, S. R. & Weissman, I. L. Tracking single hematopoietic stem cells
1314 in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. *Nat.*
1315 *Biotechnol.* (2011). doi:10.1038/nbt.1977
- 1316 12. San Filippo, J., Sung, P. & Klein, H. Mechanism of Eukaryotic Homologous Recombination.
1317 *Annu. Rev. Biochem.* **77**, 229–257 (2008).
- 1318 13. Yeh, C. D., Richardson, C. D. & Corn, J. E. Advances in genome editing through control of

- 1319 DNA repair pathways. *Nat. Cell Biol.* **21**, 1468–1478 (2019).
- 1320 14. Wang, J. *et al.* Homology-driven genome editing in hematopoietic stem and progenitor cells
1321 using ZFN mRNA and AAV6 donors. *Nat. Biotechnol.* **33**, 1256–1263 (2015).
- 1322 15. Weinreb, C., Rodriguez-Fraticelli, A., Camargo, F. D. & Klein, A. M. Lineage tracing on
1323 transcriptional landscapes links state to fate during differentiation. *Science (80-.)*. (2020).
1324 doi:10.1126/science.aaw3381
- 1325 16. Wagenblast, E. *et al.* Functional profiling of single CRISPR/Cas9-edited human long-term
1326 hematopoietic stem cells. *Nat. Commun.* **10**, (2019).
- 1327 17. Bai, T. *et al.* Expansion of primitive human hematopoietic stem cells by culture in a
1328 zwitterionic hydrogel. *Nat. Med.* **25**, 1566–1575 (2019).
- 1329 18. Genovese, P. *et al.* Targeted genome editing in human repopulating haematopoietic stem
1330 cells. *Nature* **510**, 235–240 (2014).
- 1331 19. Dever, D. P. *et al.* CRISPR/Cas9 β -globin gene targeting in human haematopoietic stem
1332 cells. *Nature* **539**, 384–389 (2016).
- 1333 20. McKenna, A. *et al.* Whole-organism lineage tracing by combinatorial and cumulative
1334 genome editing. *Science (80-.)*. (2016). doi:10.1126/science.aaf7907
- 1335 21. Kalhor, R. *et al.* Developmental barcoding of whole mouse via homing CRISPR. *Science*
1336 *(80-.)*. (2018). doi:10.1126/science.aat9804
- 1337 22. van Overbeek, M. *et al.* DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-
1338 Mediated Breaks. *Mol. Cell* (2016). doi:10.1016/j.molcel.2016.06.037
- 1339 23. Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by
1340 CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol.* (2018).
1341 doi:10.1038/nbt.4192
- 1342 24. Rago, C., Vogelstein, B. & Bunz, F. Genetic knockouts and knockins in human somatic cells.
1343 *Nat. Protoc.* (2007). doi:10.1038/nprot.2007.408
- 1344 25. Khan, I. F., Hirata, R. K. & Russell, D. W. AAV-mediated gene targeting methods for human
1345 cells. *Nat. Protoc.* (2011). doi:10.1038/nprot.2011.301
- 1346 26. Bak, R. O., Dever, D. P. & Porteus, M. H. CRISPR/Cas9 genome editing in human
1347 hematopoietic stem cells. *Nat. Protoc.* (2018). doi:10.1038/nprot.2017.143
- 1348 27. Naik, S. H., Schumacher, T. N. & Perié, L. Cellular barcoding: A technical appraisal.
1349 *Experimental Hematology* **42**, 598–608 (2014).
- 1350 28. Bystrykh, L. V. & Belderbos, M. E. Clonal analysis of cells with cellular barcoding: When
1351 numbers and sizes matter. in *Methods in Molecular Biology* (2016).
1352 doi:10.1007/7651_2016_343

- 1353 29. Gibson, D. G. *et al.* Enzymatic assembly of DNA molecules up to several hundred kilobases.
1354 *Nat. Methods* (2009). doi:10.1038/nmeth.1318
- 1355 30. Roth, T. L. *et al.* Reprogramming human T cell function and specificity with non-viral
1356 genome targeting. *Nature* (2018). doi:10.1038/s41586-018-0326-5
- 1357 31. Gurumurthy, C. B. *et al.* Creation of CRISPR-based germline-genome-engineered mice
1358 without ex vivo handling of zygotes by i-GONAD. *Nat. Protoc.* (2019). doi:10.1038/s41596-
1359 019-0187-x
- 1360 32. Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors.
1361 *Nat. Protoc.* (2006). doi:10.1038/nprot.2006.37
- 1362 33. Galibert, L. & Merten, O.-W. Latest developments in the large-scale production of adeno-
1363 associated virus vectors in insect cells toward the treatment of neuromuscular diseases. *J.*
1364 *Invertebr. Pathol.* **107 Suppl**, S80–S93 (2011).
- 1365 34. Grieger, J. C., Choi, V. W. & Samulski, R. J. Production and characterization of adeno-
1366 associated viral vectors. *Nature Protocols* (2006). doi:10.1038/nprot.2006.207
- 1367 35. Doria, M., Ferrara, A. & Auricchio, A. AAV2/8 vectors purified from culture medium with a
1368 simple and rapid protocol transduce murine liver, muscle, and retina efficiently. *Hum. Gene*
1369 *Ther. Methods* (2013). doi:10.1089/hgtb.2013.155
- 1370 36. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* (2013).
1371 doi:10.1038/nprot.2013.143
- 1372 37. Boitano, A. E. *et al.* Aryl hydrocarbon receptor antagonists promote the expansion of human
1373 hematopoietic stem cells. *Science* (80-.). **329**, 1345–1348 (2010).
- 1374 38. Fares, I. *et al.* Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-
1375 renewal. *Science* (80-.). **345**, 1509–1512 (2014).
- 1376 39. Schirotti, G. *et al.* Preclinical modeling highlights the therapeutic potential of hematopoietic
1377 stem cell gene editing for correction of SCID-X1. *Sci. Transl. Med.* **9**, (2017).
- 1378 40. Lux, C. T. *et al.* TALEN-Mediated Gene Editing of HBG in Human Hematopoietic Stem
1379 Cells Leads to Therapeutic Fetal Hemoglobin Induction. *Mol. Ther. - Methods Clin. Dev.*
1380 (2019). doi:10.1016/j.omtm.2018.12.008
- 1381 41. Cromer, M. K. *et al.* Global Transcriptional Response to CRISPR/Cas9-AAV6-Based
1382 Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. *Mol. Ther.* (2018).
1383 doi:10.1016/j.ymthe.2018.06.002
- 1384 42. Schirotti, G. *et al.* Precise Gene Editing Preserves Hematopoietic Stem Cell Function
1385 following Transient p53-Mediated DNA Damage Response. *Cell Stem Cell* **24**, 551-565.e8
1386 (2019).

- 1387 43. De Ravin, S. S. *et al.* CRISPR-Cas9 gene repair of hematopoietic stem cells from patients
1388 with X-linked chronic granulomatous disease. *Sci. Transl. Med.* **9**, (2017).
- 1389 44. Petrillo, C. *et al.* Cyclosporine H Overcomes Innate Immune Restrictions to Improve
1390 Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. *Cell Stem*
1391 *Cell* **23**, 820-832.e9 (2018).
- 1392 45. Clement, K. *et al.* CRISPResso2 provides accurate and rapid genome editing sequence
1393 analysis. *Nature Biotechnology* **37**, 224–226 (2019).
- 1394 46. Brinkman, E. K., Chen, T., Amendola, M. & Van Steensel, B. Easy quantitative assessment
1395 of genome editing by sequence trace decomposition. *Nucleic Acids Res.* (2014).
1396 doi:10.1093/nar/gku936
- 1397 47. Magoč, T. & Salzberg, S. L. FLASH: Fast length adjustment of short reads to improve
1398 genome assemblies. *Bioinformatics* (2011). doi:10.1093/bioinformatics/btr507
- 1399 48. Lassmann, T. TagDust2: A generic method to extract reads from sequencing data. *BMC*
1400 *Bioinformatics* **16**, 24 (2015).
- 1401 49. Thielecke, L., Cornils, K. & Glauche, I. GenBaRcode: A comprehensive R-package for
1402 genetic barcode analysis. *Bioinformatics* (2020). doi:10.1093/bioinformatics/btz872
- 1403 50. Del Core Luca, Montini Eugenio, Di Serio Clelia, C. A. Dealing with Data Evolution and
1404 Data Integration: An approach using Rarefaction. in *49th Scientific meeting of the Italian*
1405 *Statistical Society* (2018).

1406

1407 **ACKNOWLEDGEMENTS**

1408 We thank all members of LN's laboratory for discussion, the IRCCS San Raffaele Hospital
1409 Flow Cytometry facility (FRACTAL), the IRCCS San Raffaele Center for Omics Sciences (COSR),
1410 A. Auricchio and M. Doria (Telethon Institute of GENetics and Medicine, the TIGEM Vector Core,
1411 Pozzuoli, Italy) for providing AAV6 vectors, L. Periè (Institute Curie, Paris, France) and J. Urbanus
1412 (the Netherlands Cancer Institute, Amsterdam, the Netherlands) for advice on the BAR cloning
1413 strategy, G. Schiroli (SR-Tiget) for initial help with the design of the BAR-Seq strategy, **D. Lazarevic**
1414 **(COSR) for the help with BAR-Seq amplicon sequencing and A. Calabria (SR-Tiget) for the help**
1415 **with richness estimation.** This work was supported by grants to: LN from Telethon (TIGET grant
1416 E4), the Italian Ministry of Health (PE-2016-02363691; E-Rare-3 JTC 2017), the Italian Ministry of
1417 University and Research (PRIN 2017 Prot. 20175XHBPN), the EU Horizon 2020 Program
1418 (UPGRADE), and from the Louis-Jeantet Foundation through the 2019 Jeantet-Collen Prize for
1419 Translational Medicine; PG from Telethon (TIGET grant E3) and the Italian Ministry of Health (GR-
1420 2013-02358956). SF conducted this study as partial fulfillment of their Ph.D. in Molecular Medicine,

1421 International Ph.D. School, Vita-Salute San Raffaele University (Milan, Italy). AJ conducted this
1422 study as partial fulfillment of his Ph.D. in Translational and Molecular Medicine - DIMET, Milano-
1423 Bicocca University (Monza, Italy).

1424

1425 **AUTHOR CONTRIBUTIONS**

1426 S.F., P.G., and L.N conceived and developed the protocol. S.B., D.C., I.M. developed the BAR-Seq
1427 bioinformatic pipeline. S.B. and I.M. developed the online BAR-Seq tool. S.F., A.J., A.L. and P.G.
1428 developed and optimized the gene editing protocol. S.F., S.B., A.J., P.G., I. M., L.N. wrote the
1429 manuscript.

1430

1431 **COMPETING INTEREST**

1432 L.N. and P.G. are inventors of patents on applications of gene editing in HSPCs owned and managed
1433 by the San Raffaele Scientific Institute and the Telethon Foundation, including a patent application
1434 on improved gene editing filed by S.F., A.J., P.G. and L.N. L.N. is founder and quota holder and P.G.
1435 is quota holder of GeneSpire, a startup company aiming to develop *ex vivo* gene editing in genetic
1436 diseases. All other authors declare no conflict of interest.

1437

1438 **FIGURE LEGENDS**

1439 **Figure 1. BAR-Seq pipeline for clonal tracking of edited cells. a**, Schematics of the gene editing
1440 outcomes upon nuclease-induced DNA double strand break. BAR-Seq allows clonal tracking of cells
1441 edited by HDR. **b**, Experimental workflow of the BAR-Seq pipeline.

1442

1443 **Figure 2. Alternative configurations and generation of the BAR-Seq HDR template library. a**,
1444 Schematics of the BAR-Seq HDR template showing the possible configurations for BAR cloning,
1445 either outside (top) or inside (bottom) of an expression cassette. In the latter configuration, BAR will
1446 be transcribed with the gene of interest. Red arrows indicate primer binding sites for the assessment
1447 of BAR-Seq library diversity. **b**, Alternative PCR configurations for BAR amplification after
1448 integration. The “In-Out” PCR approach exclusively amplifies on-target HDR-integrated BARs. Red
1449 arrows indicate primer binding sites for the generation of BAR-Seq amplicon from edited cells. **c**,
1450 Schematic representation of the experimental procedure and expected results for the BAR-Seq library
1451 generation (steps 1-46).

1452

1453 **Figure 3. BAR-Seq bioinformatic pipeline.** Workflow of the BAR-Seq pipeline with representative
1454 results.

1455

1456 **Figure 4. Web application for BAR-Seq bioinformatic analyses.** Graphic interface of the
1457 homepage with demo samples uploaded (top left) and of the result page (right) reporting also sharing
1458 as heatmap (bottom left).

1459

1460 **Figure 5. Anticipated results of the BAR-Seq pipeline. a,** Expected outputs of the BAR-Seq web
1461 application upon submission of sequencing data of highly diverse (top) or poorly diverse (bottom)
1462 plasmid/viral libraries. **b,** Agilent 4200 traces of two amplicon library preparations.

1463

1464

1465

BOX 1: Diversity assessment of the BAR-Seq plasmid library

1466

EXTRA-REAGENTS

1467

- Primers (Sigma-Aldrich, Metabion or another vendor; see **Supplementary Table 3** for ordering details)

1468

1469

1470

PROCEDURE

1471

TIMING – 3 days

1472

- 1 Amplify by PCR the BAR region from the plasmid library, purify the amplicon product and deep sequence by following steps from 104 to 112. For the first PCR step, primers (“Vector_PCR1”; see **Supplementary Table 3**) must be both designed to bind the viral library sequence and to flank the BAR. For the second PCR step, primers (“Vector_PCR2”) are listed in **Supplementary Table 3**.

1473

1474

1475

1476

1477

- 2 Process sequencing data by following steps from 120 to 126 (alternatively from 113 to 119).

1478

1479

BOX 2: Diversity assessment of the BAR-Seq viral library

1480

EXTRA-REAGENTS

1481

- DpnI (New England Biolabs, cat. no. R0176L)
- DNeasy Blood and Tissue Kit (QIAGEN, cat no. 69504)

1482

1483

- Primers (Sigma-Aldrich, Metabion or another vendor; see **Supplementary Table 3** for ordering details)

1484

1485

1486

EXTRA-BIOLOGICAL MATERIAL

- 1487 ▪ K-562 cell line (ATCC, cat. no. CCL-243, RRID:CVCL_0004)
1488 https://scicrunch.org/resolver/RRID:CVCL_0004
1489 ! CAUTION – *The cell lines used in your research should be regularly checked to ensure they*
1490 *are authentic and are not infected with mycoplasma.*

1491

1492 PROCEDURE

1493 TIMING – 4 days

1494 ! CAUTION – *This procedure must be performed in sterile hood.*

1495 CRITICAL STEP – *Cell lines highly permissive to transduction with the viral vector of interest*
1496 *(e.g K-562) should be used to assess the diversity of the BAR-Seq library.*

- 1497 1 Transduce $1-10 \times 10^6$ K-562 cells with an appropriate volume of the BAR-Seq **viral library** from
1498 step 48. We advise to transduce cells at high multiplicity of infection (**MOI = 100 transducing**
1499 **units/mL for IDLV; MOI = 10^4 for AAV**). Incubate transduced cells for 24 h at 37°C in a 5%
1500 CO₂ and 20% O₂ humidified atmosphere.

1501 CRITICAL STEP – *The number of transduced cells and the MOI are critical parameters in*
1502 *order to exhaustively sequence the BAR-Seq viral library and may vary accordingly to the*
1503 *expected library complexity and diversity. To be conservative, the values given above are*
1504 *suitable for libraries with expected complexity $<10^6$.*

- 1505 2 Collect transduced cells in a suitable sterile Falcon tube, add 10 volumes of DPBS and pellet
1506 them using the centrifuge 5810R (1100 rpm, room temperature, 10 min).

1507 PAUSE STEP – *The cell pellet may be frozen at -80°C for long-term storage.*

- 1508 3 Extract the DNA using the DNeasy Blood and Tissue Kit, accordingly to manufacturer's
1509 instructions. Use a NanoDrop spectrophotometer to quantify DNA concentration.

- 1510 4 (Optional) Set up digestion reactions of the DNA from the previous step with the methylation-
1511 sensitive restriction enzyme DpnI to cleave and drop out residual plasmid contaminants.

1512

Component	Amount
DNA	5 μ L
10X CutSmart buffer	5 μ L
DpnI	2 μ L
Molecular-grade H ₂ O	38 μ L

1513

1514 PAUSE STEP – *DNA can be frozen at -20°C for storage.*

- 1515 5 Amplify by PCR the BAR region, purify the amplicon product and deep sequence by
1516 following steps from 104 to 112. For the first PCR step, primers (“Vector_PCR1”; see
1517 **Supplementary Table 3**) must be both designed to bind the viral library sequence and to
1518 flank the BAR. For the second PCR step, primers (“Vector_PCR2”) are listed in
1519 **Supplementary Table 3**.
- 1520 6 Process sequencing data by following steps from 120 to 126 (alternatively from 113 to 119).

1521

1522 **BOX 3: Clonogenic *in vitro* assay of edited HSPCs:**

1523 EXTRA-REAGENTS

- 1524 ■ MethoCult H4434 Classic (StemCell Technologies, cat. no. 04434)

1525

1526 PROCEDURE

1527 **TIMING – day ‘+4’ of the editing protocol – 1 hour**

1528 ! CAUTION – *This procedure must be performed in sterile hood.*

- 1529 1 Count the number of viable HSPCs.
- 1530 2 For each experimental condition, prepare 6 mL of methylcellulose-based medium
1531 supplemented with 100 IU/mL penicillin, 100 µg/mL streptomycin, 2% (vol/vol) glutamine
1532 in a 15 mL Falcon tube.
- 1533 3 For each experimental condition, collect 2,400 cells and add them to the supplemented
1534 medium from step 2. Thoroughly vortex and incubate 10 min at room temperature.
- 1535 4 For each experimental condition, seed three wells (triplicate) of P6-well plate with 1.5 mL of
1536 the medium from step 3 (~600 cells/well).

1537 CRITICAL STEP – *Reverse pipetting technique is recommended due to viscosity of*
1538 *methylcellulose media and to avoid bubbles formation. We also advise to pipette 1.5 mL by*
1539 *pipetting two times 750 µL using the L-1000XLS+ pipette.*

- 1540 5 Incubate for **14 days** at 37°C in a 5% CO₂ and 20% O₂ humidified atmosphere.

- 1541 6 Count the number of colonies in each well.

1542

1543 **BOX 4: Phenotypic characterization of edited HSPCs *in vitro*:**

1544 EXTRA-REAGENTS

- 1545 ■ Anti-human CD34-PE-Cy7, Clone 8G12 (BD Biosciences, cat. no. 348811, RRID:
1546 [AB_2868855](https://scicrunch.org/resolver/RRID:AB_2868855)) https://scicrunch.org/resolver/RRID:AB_2868855
- 1547 ■ Anti-human CD133/2-PE, Clone REA816 (Miltenyi Biotec, cat. no. 130-112-157, RRID:
1548 [AB_2654900](https://scicrunch.org/resolver/RRID:AB_2654900)) https://scicrunch.org/resolver/RRID:AB_2654900

1549 ▪ Anti-human CD90-APC, Clone 5E10 (BD Biosciences, cat. no. 559869, RRID: AB_398677)
1550 https://scicrunch.org/resolver/RRID:AB_398677

1551 ▪ 7-AAD Viability Staining Solution (BioLegend, cat. no. 420404)

1552

1553 PROCEDURE

1554 TIMING – day ‘+7’ of the editing protocol – 2 hours

1555 1 Collect >50,000 cultured HSPCs in an individual new FACS tube for each experimental
1556 condition.

1557 2 Add the dedicated anti-human antibodies for cell phenotypic characterization and incubate for
1558 15 min at 4°C.

1559

Target	Fluorochrome	Working Dilution	Amount x 100µl (each reaction)
CD34 ⁺	PE-Cy7	(1:40)	2.5 µL
CD133 ⁺	PE	(1:40)	2.5 µL
CD90 ⁺	APC	(1:65)	1.5 µL

1560

1561 3 Wash the cells by filling the tube with DPBS + 2% FBS and pellet them using the centrifuge
1562 5810R (1100 rpm, room temperature, 10 min).

1563 PAUSE STEP – *The stained sample may be kept at 4°C for up to 1-2 hours.*

1564 4 Add 1 µL of 7-AAD to each sample for live/dead staining and briefly mix by vortexing.

1565 5 Incubate for 10 min and then perform flowcytometry analysis with BD FACS Canto II.

1566

1567 **BOX 5: Quantification of HDR editing efficiency in *in vitro* edited HSPCs:**

1568 EXTRA-REAGENTS

1569 ▪ TTC5 HEX (20X) PrimePCR ddPCR Copy Number Assay: TTCA, Human (Biorad, cat. no.
1570 dHSACP2506733)

1571 ▪ ddPCR Supermix for Probes (no dUTP) (Biorad, cat. no. 1863024)

1572 ▪ DG8 Cartridges for QX200/QX100 Droplet Generator (Biorad, cat. no. 1864008)

1573 ▪ Droplet generation oil for probes (Biorad, cat. no. 1863005)

1574 ▪ Eppendorf twin.tec PCR plate, 96 well, semi-skirted (Eppendorf, cat. no. 951020303)

1575 ▪ Custom primers and FAM probe specific for the HDR-edited locus (Sigma-Aldrich,
1576 Metabion or another vendor; primers and probes used in⁹ for the *AAVS1* locus are listed
1577 below)

<i>AAVSI 3'</i> integration donor- genome junction	FW	GATTGGGAAGACAATAGCAG
	RV	TCTTGGGAAGTGTAAGGAAG
	Probe (FAM)	CCAGATAAGGAATCTGCCTA

1578

1579 EXTRA-EQUIPMENT

- 1580 ▪ BioRad Automated Droplet Generator (Bio-Rad, cat no. 1864101)
- 1581 ▪ BioRad PX1 PCR Plate Sealer (Bio-Rad, cat. no. 1814000)
- 1582 ▪ BioRad QX200 Droplet Reader (Bio-Rad, cat no. 1864003)
- 1583 ▪ QuantaSoft™ Analysis Pro software (Bio-Rad)

1584 PROCEDURE

1585 TIMING – day ‘+7’ of the editing protocol – 6 hours

- 1586 1 Collect up to 50,000 cultured HSPCs for each experimental condition, add 10 volumes of
1587 DPBS and pellet them using the centrifuge 5430 (2250 rpm, room temperature, 10 min).
- 1588 2 Aspirate and discard the supernatant.
1589 PAUSE STEP – *The cell pellet can be frozen at -80°C for long-term storage.*
- 1590 3 Extract gDNA using the QIAamp DNA Micro Kit, accordingly to manufacturer’s instructions.
1591 Use a NanoDrop spectrophotometer to quantify DNA concentration.
1592 PAUSE STEP – *gDNA can be frozen at +4 or -20°C for short- or long-term storage,*
1593 *respectively.*
- 1594 4 Prepare PCR mix and add gDNA material in a semi-skirted PCR microplate.
1595

Component	Amount (each reaction)
gDNA	5 ng (or up 5 µL)
ddPCR Supermix for Probes (no dUTP)	11 µL
ddPCR custom primers/probe FAM assay (20X)	1.1 µL
Human TTC5 HEX assay (20X)	1.1 µL
Molecular-grade H ₂ O	Up to 22 µL

1596

1597 ! CAUTION – *This procedure must be performed in DNA/RNA-free hood.*

- 1598 5 Proceed to droplet formation according to the manufacturer’s instructions (Bio-Rad).
- 1599 6 Seal the plate with a pierceable foil and load the PCR reactions on a thermocycler machine
1600 using the following PCR program.

1601

Step	Number of cycles	Temperature	Duration
1	1	95°C	10 min
2	40	94°C	30 sec
		T _m – 55°C	1 min
		72°C	depending on amplicon length
3	1	98°C	10 min
4	1	4°C	-

1602

1603 7 Proceed to plate reading and analyze results according to the manufacturer’s instructions (Bio-
1604 Rad).

1605 CRITICAL STEP – *The percentage of alleles carrying HDR-mediated integration can be*
1606 *calculated as follow: no. of targeted locus⁺ droplets / no. of TTC5⁺ droplets x 100. If targeting*
1607 *a sexual chromosome in male cells, the result of the formula must be multiplied by 2 in order*
1608 *to fit with the TTC5 reference gene used for normalization, which is located in an autosomal*
1609 *chromosome. In this case, the percentage of alleles carrying HDR-mediated integration*
1610 *corresponds to the percentage of HDR-edited cells.*

1611

1612 **BOX 6: Quantification of the NHEJ editing efficiency in *in vitro* edited HSPCs:**

1613 EXTRA-REAGENTS

- 1614 ▪ T7 Endonuclease I (New England Biolabs, cat. no. M0302L)
- 1615 ▪ Custom primers specific for the locus of interest (Sigma-Aldrich, Metabion or
1616 another vendor; primers used in⁹ for the *AAVSI* locus are listed below)

NHEJ <i>AAVSI</i>	FW	GCCCTGGCCATTGTCACTTT
	RV	GGACTAGAAAGGTGAAGAGCC

1617

1618 PROCEDURE

1619 TIMING – day ‘+7’ of the editing protocol – 5 hours

1620 CRITICAL STEP – *Primers must be specific for the locus of interest and amplify a sequence*
1621 *between 500-1000 bp length.*

1622 1 Set up a PCR mix as follow:

1623
1624
1625

CRITICAL STEP – *gDNA material extracted for quantification of HDR efficiency can be used for this analysis.*

Component	Amount (each reaction)
gDNA (from Box 5)	50-100 ng
5X GoTaq® reaction buffer	5 µL
MgCl₂ (25 mM)	4 µL
dNTPs (10 mM)	1.2 µL
Primer Fw (100 µM)	0.5 µL
Primer Rv (100 µM)	0.5 µL
GoTaq G2 DNA Polymerase (5U/µl)	0.5 µL
Molecular-grade H₂O	Up to 50 µL

1626
1627
1628
1629

- 2 Seal the plate with a new pierceable foil, briefly mix and spin. Load the PCR reactions on a thermocycler machine using the following PCR program:

Step	Number of cycles	Temperature	Duration
1	1	95°C	10 min
2	40	95°C	45 sec
		T _m – 5°C	30 sec
		72°C	30 sec
3	1	72°C	10 min
4	1	4°C	-

1630
1631
1632
1633

- 3 Immediately run an annealing program as follow. The annealing step is crucial to generate sequence mismatches.

Step	Number of cycles	Temperature	Duration
1	1	95°C (-2°C/s)	10 min

2	1	85°C (- 0.1°C/s)	1 min
3	1	75°C (- 0.1°C/s)	1 min
4	1	65°C (- 0.1°C/s)	1 min
5	1	55°C (- 0.1°C/s)	1 min
6	1	45°C (- 0.1°C/s)	1 min
7	1	35°C (- 0.1°C/s)	1 min
8	1	25°C (- 0.1°C/s)	1 min
9	1	4°C	-

1634

1635

- 4 Set up an enzymatic digestion of the PCR products with the T7 endonuclease as follow:

1636

Component	Amount
PCR product	20 µL
10X NEB2 buffer	2,5 µL
T7	0,5 µL
Molecular-grade H₂O	2 µL

1637

1638

- 5 Incubate at 37°C for maximum 60 min. Do not exceed with the digestion time to avoid unspecific cleavage.

1639

1640

PAUSE STEP – PCR products can be frozen at -20°C before purification.

1641

- 6 Equilibrate at room temperature the High Sensitivity D1000 Reagents and ScreenTape for 20 min.

1642

1643

- 7 Vortex High Sensitivity D1000 Reagents for 30 sec.

1644

- 8 To verify for nuclease activity, load on Agilent 4200 TapeStation the digested PCR products following manufacturer's instructions.

1645